



This is a repository copy of *Microvesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/117711/>

Version: Accepted Version

Article:

Ridger, V.C., Boulanger, C.M. orcid.org/0000-0003-4163-669X, Angelillo-Scherrer, A. et al. (16 more authors) (2017) Microvesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. *Thromb Haemost*, 117 (7). pp. 1296-1316. ISSN 0340-6245

<https://doi.org/10.1160/TH16-12-0943>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

**MICROVESICLES in VASCULAR HOMEOSTASIS and DISEASES:
A POSITION PAPER of the
ESC Working Group on Atherosclerosis and Vascular Biology**

Ridger VC^{1*}, Boulanger CM^{2,3*}, Angelillo-Scherrer A^{4,5}, Badimon L^{6,7}, Blanc-Brude O^{2,3}, Bochaton-Piallat ML⁸, Boilard E⁹, Buzas EI¹⁰, Caporali A¹¹, Dignat-George F^{12, 13}, Evans PC¹, Lacroix R^{12, 13}, Lutgens E^{14, 15}, Ketelhuth DFJ¹⁶, Nieuwland R¹⁷, Toti F¹⁸, Tuñón J^{19, 20}, Weber C^{15, 21}, Hoyer IE²².

Affiliations:

- ¹ Department of Infection, Immunity and Cardiovascular Disease, Faculty of Medicine, Dentistry and Health and the INSIGNEO Institute for In Silico Medicine, University of Sheffield, Sheffield, UK
² INSERM UMR-S 970, Paris Cardiovascular Research Center – PARCC, Paris, France
³ Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
⁴ Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
⁵ Department of Clinical Research, University of Bern, Bern, Switzerland.
⁶ Cardiovascular Research Center (CSIC-ICCC), IIB-Sant Pau, Barcelona, Spain
⁷ Cardiovascular Research Chair, UAB, Barcelona, Spain
⁸ Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
⁹ Centre de Recherche du CHU de Québec, Université Laval, Department of Infectious diseases and Immunity, Quebec City, Canada
¹⁰ Semmelweis University, Department of Genetics, Cell- and Immunobiology, Budapest, Hungary
¹¹ University/British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK
¹² Aix-Marseille University, INSERM, VRCM, UMR-S1076, UFR de Pharmacie, Marseille, France
¹³ Department of Hematology and Vascular Biology, CHU La Conception, APHM, Marseille, France
¹⁴ Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, The Netherlands
¹⁵ Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, D 80336 Munich, Germany
¹⁶ Cardiovascular Medicine Unit, Center for Molecular Medicine, Department of Medicine, Karolinska Institute, Karolinska University Hospital, SE-17176 Stockholm, Sweden
¹⁷ Laboratory of Experimental Clinical Chemistry, Vesicle Observation Center, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
¹⁸ Faculty of Pharmacy, UMR CNRS 7213, University of Strasbourg, Strasbourg, France
¹⁹ IIS-Fundación Jiménez Díaz, Madrid, Spain
²⁰ Autónoma University, Madrid, Spain
²¹ Cardiovascular Research Institute Maastricht (CARIM), 6229 ER Maastricht, The Netherlands
²² Laboratory of Clinical Chemistry and Hematology, UMC Utrecht, Netherlands

* equal contribution to this manuscript

Correspondence:

Victoria Ridger, PhD, Department of Infection, Immunity and Cardiovascular Disease, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK -- v.c.ridger@sheffield.ac.uk

Chantal M. Boulanger, PhD, INSERM UMR-S 970, Paris Cardiovascular Research Center – PARCC, 56 rue Leblanc, 75015 Paris, France – Chantal.boulanger@inserm.fr

Word number =8727/8000

Reference number = 330

Figures= 6

Table = 2

Acknowledgments:

A. Angelillo-Scherrer was supported by the Swiss National Foundation for Scientific Research grants 310030_153436

L Badimon was supported by Spanish Ministry of Science, Plan Estatal I+D+I 2013-2016 [SAF2013-42962-R] and TerCel (Red de Terapia Celular) [RD/12/0019/0026].

ML Bochaton-Piallat was supported by the Swiss National Foundation for Scientific Research grants 310030_166357

E Boilard is recipient of an award from the Canadian Institutes of Health Research

O Blanc-Brude was supported by the Agence Nationale pour la Recherche ANR-11-IDEX-05-02 Recherche-USPC 'HEMIR'.

C Boulanger was supported by the National Institute for Health and Medical Research (INSERM), the National Agency for Research (ANR-2011-META-miRA; ANR-2016-Cardinal) and the Fondation de France (Engt-2012-00029497).

E Buzas was supported by grants OTKA #120237 & #111958, MEDINPROT and NVKP_16 (National Heart Program).

A Caporali (FS/11/52/29018), **P Evans** (RG/13/1/30042) and **V Ridger** (PG14/38/30862; FS/14/8/30605) were supported by the British Heart Foundation.

F Dignat-George and **R Lacroix** were supported by Aix Marseille University (AMU), the National Institute for Health and Medical Research (INSERM) and Amidex* (AAP Emergence VINTAGE 2014.)

D Ketelhuth is supported by the Swedish Heart-Lung Foundation, and Karolinska Institute Cardiovascular Program Career Development Grant.

E Lutgens was supported by Deutsche Forschungsgemeinschaft (SFB1123-A5), the European Research Council (ERC Con °681493), and the Netherlands Organisation for Scientific Research (NWO) (VICI).

C Weber was supported by Deutsche Forschungsgemeinschaft (SFB1123-A1/B4) and European Research Council (ERC AdG °692511).

Abbreviations:

APC: Activated protein C

CD40L: CD40 ligand

CRP-XL: cross-linked collagen related peptide

Del-1: developmental endothelial locus 1

EPCR: endothelial protein C receptor

EVs: extracellular vesicles

ICAM: intercellular cell adhesion molecule

IL: interleukin

LDLR: low-density lipoprotein receptor

LPS: lipopolysaccharide

miRNA: micro RNA

MVs: microvesicles

NF- κ B: nuclear factor kappa-b

NTA: nanoparticle tracking analysis

PECAM: platelet endothelial cell adhesion molecule

pre-miRNAs: precursor microRNAs

PS: phosphatidylserine

RBC: red blood cell

ROCK: Rho-associated protein kinase

SOCE: Stored Operated Channels

SPRi: surface plasmon resonance imaging

TF: tissue factor

TNF- α : tumor necrosis factor α

TRAIL: TNF related apoptosis-inducing ligand

TRPS: tunable resistive pulse sensing

VEGF: vascular endothelial growth factor

VEGF-R2: VEGF receptor 2

Abstract:

Microvesicles are members of the family of extracellular vesicles shed from the plasma membrane of activated or apoptotic cells. Microvesicles were initially characterized by their pro-coagulant activity and described as “microparticles”. There is mounting evidence revealing a role for microvesicles in intercellular communication, with particular relevance to hemostasis and vascular biology. Coupled with this, the potential of microvesicles as meaningful biomarkers is under intense investigation. This review will summarize the current knowledge on the mechanisms of formation and composition of microvesicles of endothelial, platelet, red blood cell and leukocyte origin. This paper will also review and discuss the different methods used for their analysis and quantification, will underline the potential biological roles of these vesicles with respect to vascular homeostasis and thrombosis and define important themes for future research.

1. Introduction

Microvesicles (MVs) belong to the family of extracellular vesicles (EVs), including exosomes and apoptotic bodies, shed from activated or apoptotic cells. These extracellular vesicles are distinguished on the basis of their subcellular origin, their size, their content and the mechanism leading to their formation.

MVs were initially characterized by their pro-coagulant activity. Seminal work demonstrated that platelet-deprived plasma could support coagulation and that its clotting property was abrogated by high-speed centrifugation (1, 2). Wolf identified the phospholipid-containing material, derived from platelets and capable of supporting coagulation, as *platelet dust*, subsequently called microparticles (2, 3). For these historical reasons, the term *microparticle* is the most commonly employed to refer to extracellular vesicles generated from platelets in the fields of hemostasis and thrombosis. The term *microvesicle*, however, is utilized within this review for consistency, and refers to extracellular vesicles produced by cytoplasmic membrane blebbing and shedding (2, 4), and is distinguishable from the vesicles stored in multivesicular bodies or alpha-granules, called exosomes (5, 6).

Today, MVs are interesting biomarkers with potential prognosis value as their content (proteins, active lipids, miRNA) (7, 8) varies with the inducer that initiated their shedding and with the severity of the disease (9-14). In addition, MVs emerge as new regulators of cellular crosstalk, in particular in vascular biology.

The present Position Paper, rather than systematically reviewing the literature, will critically summarize the current knowledge on the mechanisms of formation of MVs, their cellular origin, their composition, and the methods used for their analysis and quantification; potential pitfalls in MV quantification and functional effects will be discussed. In addition, this review will enlighten the potential biological roles of these vesicles with respect to vascular homeostasis and thrombosis.

2. Microvesicle formation

2.1. Phospholipid transbilayer and phosphatidylserine exposure

The asymmetry of phospholipid distribution across the plasma membrane is a common feature of resting eukaryotic cells. Conversely, loss of asymmetry is a driving force for plasma membrane remodelling, i.e. lipid motion and membrane deformation. Modification of the monolayer content in diffusible molecules alters lipid packing and causes membrane instability, regulated by sphingomyelinases that produce diffusible ceramides and prompt PS and phosphatidylcholine translocation and membrane budding (15-17). Whether ceramides and inner-leaflet interacting annexins also prompt agonist-driven MV release is unknown (18, 19). Other membrane adaptors, like arrestin-domain-containing-protein 1, appear to mediate the release of small plasma membrane vesicles of undetermined composition (20). The recently identified crowding effect of integral asymmetric proteins with large ectodomains and smaller intracellular ones also favours membrane bending in liposomes (21). Whether integrins that are highly distributed in platelets, endothelial cells or leukocytes take part in crowding-driven budding effects remains unknown (22, 23).

In resting cells, spontaneous phospholipid transbilayer transport is very slow (1 lipid/24h) (15, 24). Asymmetry is the result of the opposing activities of ATP-dependent phospholipid transporters governing inward (flippases) or outward (floppases) translocation and of non-specific bi-directional ATP-independent lipid transporters (scramblases). During agonist-induced calcium cell stimulation, PS exposure results from (i) calcium-dependent inhibition of flippase and (ii) its rapid translocation exerted by floppase(s) and/or scramblase(s) (25-27). The calcium-dependent proteolysis of the cytoskeleton leads to an eventual transient imbalance in phospholipid density between the two leaflets driven by the swift PS egress and a lower phosphatidylcholine and sphingomyeline reverse transport (28, 29). This triggers local instability of the plasma membrane and shedding of MVs that are released upon raft clustering (30-32). The calcium-dependent channel TMEM16F (ANO6), an anoctamin, has recently been demonstrated to play a pivotal role in calcium-induced phospholipid scrambling in the release of MVs exposing PS (25, 33-36). Interestingly, TMEM16F is mutated in Scott Syndrome, a rare human inherited bleeding disorder caused by defective platelet PS membrane exposure and MV shedding also evidenced in red cells and leukocytes (34, 37-40).

The existing data in isolated cells support the concept of MVs exposing PS as a consequence of membrane randomization. PS translocation and MV release are both defective in response to procoagulant agonists in Scott syndrome, suggesting that PS exposure is a prerequisite to MV shedding (41, 42). Moreover, annexin-5, a high affinity PS ligand, inhibits MV release from stimulated cells (43). Finally, PS exposure and PS-positive MV shedding show similar time and concentration dependence whilst agonists induce distinct MV protein signatures (8, 44-47).

Important proportions of MVs lacking externalized PS, but expressing cellular markers, have been reported in cell supernatants and in plasma (4, 46, 48-50). However little is known about the nature and mechanisms of these vesicles. These observations may result from the heterogeneous nature of MVs. They may also be the result of altered membrane fluidity by exogenous proteins in addition to differences in detection thresholds (15, 43, 51). However, one cannot exclude artefacts in MV assessment/labelling, including contamination with other extracellular vesicles or

proteins, absence of calcium that dampen PS detection (annexin, lactadherin, Del-1) (43, 52, 53) or prompt fusion with other vesicles or proteins (54-57). This does not rule out the existence of these MVs derived from an, as yet, undetermined mechanism of membrane release.

The use of annexin V positivity to identify MV populations in flow cytometry analysis is widespread. However, annexin V labeling could be skewed due to the presence of phosphatidylserine on lipoproteins(58). Furthermore, the possibility of the existence of PS negative MVs may mean that a proportion of MVs are excluded from analysis should this criteria be applied. This population may indeed differ in proportion and function depending on the parent cell. The possibility remains that by excluding PS negative MVs (or those MVs that bind annexin V below the detection limit of flow cytometers) an important sub-population of MVs will remain ill-described and unstudied. In addition, it is well known that apoptotic bodies have exposed PS on their surface and caution must be taken when analysing PS positive MV populations to ensure there is no contamination with vesicles released via apoptosis.

2.2 Cytoskeleton reorganization and MV formation

The cytoskeleton and hydrostatic pressure equilibrate plasma membrane tension whereas curvature instability of the bilayer drives membrane shape fluctuations and budding. In resting platelets, α IIb β 3-mediated destabilization of the actin cytoskeleton promotes the release of procoagulant MVs, confirming that cytoskeleton integrity is critical for membrane asymmetry (59). The role of cytoskeleton reorganization in MV shedding was ascertained by inhibition of calcium-dependent proteases or actin depolymerisation that abolish MV release in stimulated platelets and megakaryocytes (60, 61) (**Figure 1**). Depending on the cell lineage, agonist-induced Ca^{2+} influx prompts the protease activity of caspases and/or calpains that cleave typical cytoskeleton proteins like filamin, gelsolin, talin and myosin (60, 62). Calpains are critical for platelet or neutrophil shedding, caspases for MV generation in vascular cells under apoptotic and non-apoptotic conditions (30, 63). Caspases mainly act through Rho kinase-dependent phosphorylation of the myosin light chain kinases (MLCK) (64-67), although Rho-kinase dependent endothelial MV formation can be independent of caspase activation (68). The release of neutrophil MVs is caspase-8 dependent and requires phosphokinase A and MLCK (69). In tumor cells, the Rho-driven cytoskeleton reorganization and its relevance to exaggerated MV shedding identifies the pivotal role of small GTP-binding proteins, such as Rab22A (70) or ARF6 (71). Finally, caspase-3 directly triggers Xkr8, a putative scramblase or caspase transducer that promotes PS exposure in the membrane of apoptotic cells (72).

3. Microvesicles methodology update

3.1 Detection of MV

Methodologies to study MVs can be classified based on detection of *single* or *multiple* MVs. The most common methods to study *single* MVs are flow cytometry, tunable resistive pulse sensing (TRPS), and nanoparticle tracking analysis (NTA). Methods to study *multiple* MVs include immunocapture-assays, functional assays, and hybrid assays that involve capture followed by function or phenotype testing. The latter, “bulk assays” offer potential for high-throughput processing of clinical samples, may be sensitive enough to take the functional contribution of small MVs into account, and can be more

cost-effective and user-friendly than single vesicle detection-based methods. However, single MV detection methods offer information on size or cellular origin of single MV, and thus may be more suitable to determine the presence of rare subtypes of MVs in a mixed population.

More recently, surface plasmon resonance imaging combined with protein microarray technology has been applied to MVs (73). An array of antibodies are printed on a gold chip, and antibody captured MVs induce a change in refractive index. Potentially, surface plasmon resonance imaging may be useful for parallel and multiple analysis of MVs in clinical body fluids (74).

3.2 Pitfalls in MV measurements

Among the single particle-based method, flow cytometry remains the most commonly used technique with the highest potential to determine the cellular origin of single MV (75-77). Over the past few years, significant improvements have been made regarding the sensitivity of flow cytometry to detect single vesicles with a diameter of < 300 nm, which have further established this methodology as the most promising tool for routine enumeration of MV subsets (78-80). Because a method has been developed to derive information on absolute size (diameter) and refractive index of single MVs and similar-sized particles from flow cytometry light scatter signals, the comparison of absolute measurement results on MV between instruments and institutes may come within reach (81, 82). However, it is important to note that accurate detection of MVs by flow cytometry is still a challenge, in particular for circulating MV analysis (56, 83-85).

NTA measures the Brownian motion of single particles in a laser beam (86) and is a valuable tool for the measurement of size distribution of MVs. The light scattered from single particles is visualized by microscopy, and the movement of single particles is monitored and recorded in time. Although NTA detects particles with a diameter < 100 nm, the resolution is low (75). The main limitation of NTA, however, is the inability to distinguish MV from similar-sized particles in suspension (i.e. debris). The ability to use the fluorescent mode offers the opportunity to specifically identify MVs. An alternative method, TRPS, is based on impedance to monitor individual MVs with a diameter of 80–1,000 nm or more, as they move through tunable nanopores (87). Particles passing the pore generate a change in the electric resistance, thus providing information on diameter, surface charge, concentration, and zeta potential of single particles. The major disadvantage of TRPS is that it cannot distinguish between MVs and similar sized particles such as chylomicrons or protein aggregates.

Each of the above methods has advantages and disadvantages. Therefore, to confirm the presence of MVs, ISEV recommends the use of a second independent method (88)[also see Section 9]. As an independent method, often transmission electron microscopy is used, because this technique has a high resolution and can distinguish intact MVs from non-MVs at the level of a single particle.

3.3 Standardization of MV measurements

Standardization is mandatory to allow evaluation of the true clinical relevance of MV at a multicenter level, and should be accompanied by continuous improvement of methods. Flow cytometry is the first method to benefit from standardization efforts coordinated by the ISTH Standardization Committee on Vascular Biology. Thus, several bead-based comparison studies have been performed to standardize light scatter gates for MV selection between instruments (76, 89). At present, additional standardization

strategies are being tested based on either absolute vesicle size approximation or fluorescence (90). In 2015, a collaborative workshop was initiated to standardize MV detection by flow cytometry (www.evflowcytometry.org). In this workshop the knowledge from three international societies is combined: International Society on Extracellular Vesicles provides knowledge on *vesicles*, International Society on Advancement of Cytometry provides knowledge on *detection of MV by flow cytometry*, and the International Society on Thrombosis and Haemostasis contributes with expertise on *blood collection, handling and storage*. Similarly, attempts are on-going to standardize TRPS measurements and coagulation.

For a long time measurement of (single) vesicles was considered as measuring “the tip of the iceberg”. Because the sensitivity of vesicle detection is improving rapidly, there is now an urgent need for developing novel guidelines regarding collection, handling and storage, as required for reliable biorepositories. Recently, a start has been made in developing such guidelines for human blood, urine and saliva using sensitive MV detection methods ((91); www.metves.eu), but more research is clearly required. Furthermore, labelling protocols for flow cytometry require updates and improvements, and standards and validation protocols need to be developed. Finally, training and education are now being developed, such as the online course developed by ISEV on the “Basics of Extracellular Vesicles”, which is open access (<https://www.coursera.org/learn/extracellular-vesicles>). In addition, the ISTH Academy has recorded two webinars on MVs. Both courses include up-to-date information on isolation and detection of MVs.

3.4 MV isolation and pitfalls in testing their functional effects

One of the most important considerations when isolating MVs from blood is the presence of contaminating platelets. When comparative studies are performed, sample preparation must be identical in order that any artefact is present in all samples (91). In most studies, MVs are isolated and/or concentrated using protocols involving either initial low or intermediate multiple centrifugations, combined with ultracentrifugation, density gradient centrifugation, or combinations thereof. These MV populations are impure and contaminated by plasma or serum proteins hence affecting the outcome of functional or -omics measurements (**Table 1**). To overcome these limitations, size exclusion chromatography has been adopted recently by many investigators to separate MVs from soluble proteins in cell preparation ((92); www.metves.eu), thereby facilitating for example detection of MVs by electron microscopy as well as -omics studies of EVs. More quantitative information is clearly needed about the extent of MV recovery for each isolation method (93).

Several questions may arise when testing MV functional effects either *in vitro* or *in vivo*. First, the choice of MV concentrations should be of physiological or pathological relevance. Surprisingly, few studies evaluate the effects of more than one concentration of MVs, although previous reports point out the paradoxical effects of different MV concentrations (94). Second, the experimental design should include robust controls, including the supernatant above the isolated MV pellet. Control experiments using saline-buffered solutions may be also an additional control. When cytokines or inhibitors are used to trigger MV release *in vitro*, caution should be taken to remove these compounds from the enriched vesicle preparation, for example by dialysis or size exclusion chromatograph, to avoid experimental bias. The presence of large numbers of

MVs and exosomes in serum used for culture experiments should also be taken into account. Similarly, presence of lipoproteins, hormones and other mediators in plasma should also be taken into account when designing adequate control experiments for testing functional effects of circulating MVs. Finally, *in vivo* effects of MV of human origin need to be tested in suitable animal models in order to avoid immune reaction to human biological material that would mask MV functional effect.

4. Microvesicles as regulators of cell communication

In 1996, Raposo et al. demonstrated that EVs could be transferred between cells (95). This concept is based on the observation that EVs released from a given cell type interact through specific receptor ligand with other cells, leading to trigger cell stimulation directly or by transferring the surface receptors (96). Since then, numerous studies confirmed that EVs are an important mode of intracellular communication and cargo delivery between cells, including platelets, endothelial cells, and monocytes. Hence, it is now recognized that EVs are an integral part of the intercellular microenvironment and act as regulators of cell-to-cell communication (**Figure 2**).

Ratajczak et al. proposed that MV-mediated cell-to-cell communication emerged very early during the evolution as one of the first communication mechanisms (97). The first evidence for MV-mediated protein transfer was observed by Barry et al. where bioactive lipids were functionally transferred via platelet MVs to endothelial cells leading to specific biological effects (98). Another example is the transfer of arachidonic acid between activated and resting platelets that results in the modulation of their procoagulant responses (99).

Since then, significant progress has been made in the field of MV transfer. However, the study of MV release and uptake within *in vitro* and *in vivo* settings remains challenging, as there are no reliable detection methods to discriminate cells that uptake EVs from cells that do not. Recently, a promising novel tool using Cre-loxP system has been developed to directly identify the fluorescently marked Cre-reporter cells that take up EVs released from Cre recombinase-expressing cells (100).

4.1 MV uptake and clearance

The mechanisms controlling vesicle uptake and internalization are still a matter of debate. Various mechanisms have been proposed, including endocytosis (101), phagocytosis (102) and plasma or endosomal membrane fusion (103). Their molecular mechanisms have been validated using antibodies to test the role of specific ligands or receptors, and chemical inhibitors to block specific uptake pathways. A recent study has shown specific differences between exosomes and MVs for transferring genetic information (104). In particular, MVs, but not exosomes, can functionally transfer loaded reporter molecules to recipient cells. These results have significant implications for the understanding of EVs role in cellular communication and further development of EVs as vehicles for macromolecule delivery.

Several studies have also demonstrated rapid clearance of MVs of different cellular origin from the circulation, mainly by liver and spleen phagocytes (55, 105-107). However, there is no definitive mechanism regarding the cell types involved in uptake and the potential consequences of such uptake. The presence of externalized PS is of vital importance for effective uptake through glycoproteins Del-1 or lactadherin bridging MV's PS and cellular integrins on endothelial cells and macrophages,

respectively (106, 108, 109). The receptor tyrosine kinases Tyro3, Axl and Mer and their ligands protein S and Gas6 are also involved in the PS-dependent uptake of MV by macrophages and endothelial cells (110). In addition, lipid raft-mediated endocytosis contributes to MV internalisation in human brain endothelial cells, but not in those originating from human umbilical vein (109, 111). MV uptake also depends upon how they are produced. For instance, stimulation of human aortic endothelial cells with tumor necrosis factor α (TNF- α) leads to the formation of two populations of MVs, with distinct miRNA content (112). MVs rich in miRNAs are taken up much faster than the other MV population, suggesting that endothelial cells could differentially recognize MVs generated upon different molecular cues.

4.2 Cargo transfer

MVs influence behaviour of target cells in multiple ways: by directly activating cell surface receptors via protein and bioactive ligands, by transfer of cell surface receptors or delivery, including transcription factors, mRNA and non-coding RNA. The bioactive ligands exposed on the MV surface are responsible for several important regulatory processes; for instance, direct stimulation of endothelial cells with MV-associated CD40 ligand (CD40L) stimulates angiogenic responses *in vivo* (113). Moreover, MVs can transfer the adhesion molecule CD41 (Integrin alpha-IIb) from platelets to endothelial cells, conferring the latter pro-adhesive properties (114). Transfer of the chemokine CCL5 (RANTES) exposed on platelet MVs to target endothelial cells by GPIIb/IIIa and JAM-A dependent mechanisms contributes to monocyte recruitment (115). Furthermore, intercellular adhesion molecule-1 (ICAM-1) is transferred, by a PS-dependent mechanism, from MVs isolated from atherosclerotic human plaques and functionally integrated into endothelial cells following membrane fusion, resulting in increased monocyte adhesion and transmigration (116).

The presence of functional mRNA in EVs was first described in 2006 for murine stem cell-derived vesicles (117). EVs, however, could also transport mRNA fragments (118), long non-coding RNA (119), miRNA (120, 121), ribosomal RNA (rRNA) (119) and fragments of tRNA-, vault- and Y-RNA (122). This concept that non-coding RNA, and specifically miRNA, are transported into extracellular spaces, together with the evidence that exchange of miRNAs between cells can be accomplished through EVs, led to a revolutionary hypothesis of the existence of a miRNA vesicle-mediated communication system. Embedding of miRNAs in EVs could explain their resistance to nucleases when released outside the cell (123, 124). A large fraction of miRNAs exported by cells also associates with the Argonaute (Ago) protein family (125). Some studies report absence of RISC complex proteins (including Ago2) in the exosomes sub-group of EVs (126), whereas others report presence of Ago2 protein (127). In this regard, RISC proteins in EVs could process precursor microRNAs (pre-miRNAs) into mature miRNAs, inducing the cell-independent microRNA biogenesis (128). This is an exiting novel area of research that requires caution due to numerous potential pitfalls in the interpretation of the data as changes in miRNA content may not result in functional changes in the target cell.

Endothelial EVs can stimulate repair by functionally influencing endothelial target cells. For instance, endothelial MVs and apoptotic bodies can transfer functional miR-126 to target endothelium to promote CXCL12-mediated angiogenic cell recruitment for atheroprotection or re-endothelialisation after endothelial injury in mice by stimulating endothelial migration and proliferation, due to downregulation of RGS16 and SPRED1, respectively (121, 129). Endothelial p75 neurotrophin receptor activates the NF- κ B

signalling, inducing miR-503 transcription and the shedding of endothelial MVs by triggering the expression of Rho kinase (130). Intriguingly, miR-503-containing endothelial MVs are taken up by pericytes *in vivo* leading to, downregulation of miR-503 target genes, EFNB2 and vascular endothelial growth factor A (VEGFA), and increased vessel permeability (130). Furthermore, miR-143 and miR-145 packaged in endothelial EVs released under shear stress are taken up by smooth muscle cells, where they downregulate target genes, inducing atheroprotective effects (131). Finally, circulating MVs from patients with coronary artery disease are deficient in Del-1, a glycoprotein mediating their endothelial uptake. *Ex vivo*, this led to a reduced uptake of MV-associated miRNAs (miR-17, miR-19a, miR-21, miR-92a, miR-146a, miR-222, and miR-223) in recipient cultured endothelial cells (132).

5. Endothelial microvesicles

The suggestion that endothelial MVs are causative agents in vascular pathology has arisen from their numerical increase in a range of diseases that have been extensively reviewed (133-135). Endothelial derived MVs carry endothelial proteins such as adhesion molecules (VE-cadherin, platelet endothelial cell adhesion molecule 1, intercellular adhesion molecule 1 (ICAM-1), E-selectin, α_v integrin), growth factors (Endoglin, S-Endo 1 (CD146), VEGF receptor 2 (VEGF-R2), hemostatic molecules (von Willebrand factor, TF, TF pathway inhibitor (TFPI), tissue plasminogen activator, plasminogen activator inhibitor 1, endothelial protein C receptor (EPCR)) or active components (Endothelial NO synthase, urokinase type plasminogen activator) (136). They have also been reported in human and murine plasma (137, 138), vitreous fluid (139) and in inflammatory lesions such as the atherosclerotic plaque or ischemic tissues (140) (**Table 2**). The composition of endothelial MVs depends upon the stimulus triggering their biogenesis, and their components originate from the plasma membrane, the cytosolic fraction, the cytoskeleton or from mitochondria (8). Elevated numbers of endothelial MVs were first reported in 1999 in disease populations, and were thus considered as potential diagnostic and prognostic biomarkers (137) (**Table 2**).

5.1 Regulation of endothelial MV formation

Circulating levels of endothelial MVs are thought to reflect a balance between cell stimulation, proliferation, apoptosis and other forms of cell death (136). Biological factors that are pertinent to vascular health and hemostasis are involved in the generation of endothelial MVs (**Figure 3**). Among them, inflammatory and coagulation factors (such as TNF- α and other inflammatory cytokines, bacterial lipopolysaccharides (LPS), reactive oxygen species, Plasminogen Activator Inhibitor, thrombin, Camptothecin, C-Reactive Protein and uremic toxins, estrogens) are able to induce *in vitro* endothelial MV generation (66, 136, 141-145). Interestingly, endogenous nitric oxide and oxidized lipids (146) also impact on MV generation by cultured cells. Although little is known on the precise mechanisms involved in endothelial MVs release *in vivo*, the role of arterial shear stress has recently been demonstrated (68, 147). Generation of endothelial MVs from the endothelium may be considered a hallmark event reflecting the beginning of endothelial dysfunction. For instance, passive exposure to cigarette smoke rapidly (within 30 minutes) increases circulating EMVs in healthy subjects concomitantly with impaired endothelial function (148).

Evaluating the intracellular transcriptional events leading to endothelial MV formation in response to thrombin evidenced an early step involving genes linked to cytoskeleton re-organisation, such as Rho-kinase ROCK-II, followed by a second step mediated by TNF related apoptosis-inducing ligand (TRAIL)/Apo2L, a cytokine belonging to the TNF- α super-family (149). The transcription factor NF- κ B was required both for the early and late production of endothelial MVs. The activation of the p38 mitogen-activated protein kinase, as well as the activation of Rho kinase and extracellular signal-regulated protein kinases 1 and 2 by low shear stress were also identified as critical pathway in the production of endothelial MV (68, 136), thus providing a paracrine loop enhancing the endothelial response to inflammation (**Figure 3**).

5.2 Multifaceted roles of endothelial MVs in vessel wall homeostasis

The expression of anionic phospholipids, especially PS, able to bind and activate coagulation factors contributes to the procoagulant potential of endothelial MVs (137, 150). Moreover, different agonists induce the generation of endothelial MVs expressing tissue factor (137, 146, 150, 151). Interestingly, endothelial MVs bind to monocytes and induce tissue factor expression and activity (152). However, the limited evidence of endothelial MV contribution *in vivo* frustrates our knowledge of their role in coagulation and thrombosis. The thrombogenic activity of endothelial MVs has been demonstrated in a mouse model after exogenous injection of TF positive endothelial MV (153). However, selective deletion of tissue factor in endothelial cells has no effect on coagulation activation in a murine model of endotoxemia (154). Therefore, the increased levels of tissue factor positive endothelial MV detected in diseases such as sickle cell or sepsis (155, 156), suggests that TF positive endothelial MV may be selectively associated to certain disease states, and possibly to subsets of endothelial MVs that remain to be characterized. Interestingly, other studies have provided evidence that endothelial MVs can also exhibit anticoagulant and vasculo-protective activity: they can deliver miR-126 or thromboxane A2 to the vessel wall (157), and can expose EPCR and activated protein C (APC). APC positive endothelial MV display anticoagulant and cytoprotective properties effects on endothelial cells through the reduction of apoptosis (158). Moreover, endothelial MV also behave as a catalyst, supporting plasmin generation by plasminogen (94), which confer them fibrinolytic properties with a pivotal role for clot dissolution. These findings illustrate the broad scope of mechanisms involving endothelial MVs in haemostasis and thrombosis, and their potential beneficial capacity to influence the evolution of the disease (**Figure 3**).

5.3 Role of endothelial MVs in inflammation.

Inflammatory mediators enhance endothelial MV biogenesis *in vitro*. An increase in endothelial MVs is evident in many inflammatory-type diseases such as atherosclerosis, diabetes or autoimmune conditions (**Table 2**). There is a direct correlation between endothelial MV number and IL-6, both *in vivo* and *in vitro*, implying a close relationship between endothelial vesiculation and classic inflammatory pathways of cytokine production (159, 160). Endothelial MVs may not only reflect the activation status of the cells but also confer further systemic activity, indicating that they are not only the consequence, but could also be involved in regulating inflammation. In addition, interaction between endothelial MV and naïve endothelial cells triggers pro-inflammatory responses assessed by up-regulation of ICAM-1 mRNA expression and soluble ICAM-1 shedding from targeted cells, an effect that was no longer observed using endothelial MV from un-stimulated endothelial cells (159). Endothelial MVs

injected intravenously in mice lead to increased systemic and pulmonary levels of IL-1 β and TNF α , correlating with an increase in neutrophils in the lung (161).

5.4 Endothelial MVs, angiogenesis and vessel remodeling.

The angiogenic effect of endothelial MVs is highly dependent on their composition. Some studies reported that endothelial MVs impair angiogenesis, but the underlying mechanism remains unclear. The role of reactive oxygen species may be important as *in vitro*, angiogenesis impairment can be rescued with a cell permeable superoxide dismutase mimetic (162). Physiological and pathological concentration of endothelial MVs injected into LDLR-/- mice on a high fat diet inhibited angiogenesis in the heart with effects on endothelial nitric oxide synthase and NO generation (163). This inhibitory effect on tube formation was also reported by MVs from diabetic patients with coronary artery disease (164). Overall it would appear that endothelial MVs inhibit angiogenesis. However, endothelial MVs from human microvascular endothelial cells were shown to induce angiogenesis at low concentration, through plasmin generation, whereas higher concentrations have opposite effect (94). Within the atherosclerotic plaque, CD40L positive MV enhance endothelial proliferation, promoting *in vivo* neovessel formation and thus favoring intra-plaque hemorrhage (113). Ligation of endothelial CD40 with CD40L positive endothelial MVs modulate VEGF and PI3K: AKT activation and cell proliferation (113). Importantly, since some endothelial MVs can both promote or inhibit angiogenesis, appropriate animal models are required in order that the effects of endogenous release can be assessed.

5.5 Conclusion

Endothelial MVs are multifaceted biological vectors playing a role in both physiological and pathological conditions. Their pleiotropic roles identify them as active intercellular communicators potentially contributing to the regulation of vascular homeostasis. Dysregulation of endothelial MV biogenesis and its biological activities may be an surrogate marker of vascular dysfunction and as such provide potential biomarkers of endothelial dysfunction (**Table 2**). Although this prospect is challenging, a fully understanding of endothelial MV biogenesis and *in vivo* demonstration of their role in pathophysiology is required and will undoubtedly uncover new areas of vascular biology.

6. Platelet microvesicles

Platelets are anucleated fragments released in the bloodstream from their cellular precursor, the megakaryocyte (165). Outnumbered in blood by RBCs only, platelets are recognized for their role in hemostasis and thrombosis. With their broad content in mediators and expression of receptors for immune regulatory functions, evidence also supports their contribution to immunity, inflammation and tissue repair (166, 167). Hence, studies reveal that vesicles released by platelets also convey an elaborate set of cargo and might play roles other than the support of coagulation and thrombosis, such as angiogenesis, cancer, cardiovascular diseases and inflammation (4, 134, 168, 169) (**Table 2**).

As the megakaryocyte is a large cell that can undergo several rounds of DNA replication without cellular division, its cytoplasm is particularly rich in miRNA and other factors, which are transferred to platelets during proplatelet formation. Thus, albeit anucleated, platelet cytoplasm contains miRNA and the miRNA machinery such as Ago2 (170),

which have been reported to be encapsulated within MVs (171). Growth factors (e.g. platelet-derived growth factor, transforming growth factor β) (172), enzymes (e.g. 12-lipoxygenase, thromboxane synthase) (98, 173), cytokines (e.g. IL-1) (174, 175), transcription factors (173) and even functional mitochondria (173, 176) (**Figure 4**) are found in platelet MVs, and can be efficiently internalized by other cells such as endothelial cells (106, 171), macrophages (55, 177), and neutrophils (173). Whereas the internalization process in endothelial cells implicates MV's PS recognition by receptors such as developmental endothelial locus-1 (Del-1) and the interaction of the receptor tyrosine kinase Axl with its ligand Gas6 found at the surface of MVs (55, 110), the internalization by neutrophils is also tightly regulated and requires 12-lipoxygenase activity present within MVs (173). Hence, platelet MVs are retrieved inside neutrophils in the joints of arthritic mice, and the ablation of the gene coding for 12-lipoxygenase (*ALOX12*) abrogates the internalization of MVs and consistently reduces inflammation.

6.1 Regulation of platelet MV production

In spite of their small size, approximately 3 μm in diameter, platelets contain an impressive membrane reservoir. The platelet plasma membrane comprises sinuous invaginations called the open canalicular system, which channels provide an important source of membrane permitting the formation of filopodia and spreading (up to 420%) on activation (178). Furthermore, impressively long (250 μm) membrane tendrils, called flow-induced protrusions, trail into the blood vessel from adherent activated platelets under flow conditions (179). Thus, although platelets are small, their abundance in blood and their important membrane content might explain how platelets represent a dominant source of MVs in blood in physiological conditions (49).

Different platelet stimuli can trigger platelet activation via different signalling pathways leading to an increase in intracellular calcium. Studies have shown distinct potencies at inducing MV release, e.g. Ca^{2+} ionophore > thrombin > the glycoprotein VI (GPVI) agonist cross-linked collagen related peptide (CRP-XL) > co-stimulation with thrombin and CRP-XL > collagen > LPS > thrombin receptor activating peptide > adenosine di-phosphate (6). Mechanistically, platelet agonists induce the rise in intracellular calcium concentration, which in turn triggers cytoskeleton cleavage through calpain activation and cellular contraction and blebbing (30, 180). In addition to platelet agonists, platelet MV formation can also be triggered by physical stimuli (shear stress, hypoxia) or prolonged storage.

6.2 Platelet MVs in physiological and pathological conditions

A combination of cryo-electronic microscopy and flow cytometry determined that the blood at steady state contains approximately 10^7 platelet MVs exposing PS per ml, pointing to a constitutive production of MVs by platelets, potentially due to shear stress and platelet aging. However, studies suggest that instead, most of the MVs in blood in fact originate from megakaryocytes (4, 60, 181). Circulating MVs originating from megakaryocytes are distinguished from those derived from activated platelets by the presence of P-selectin, lysosomal associated membrane protein 1 and immunoreceptor-based activation motif (ITAM) receptors (4, 60, 181). However, in pathological context during which platelets are activated, such as in rheumatic diseases (182), at least part of MVs in blood circulation were proven to originate from platelets (181). Whether platelet MVs contribute to the increased risks of cardiovascular diseases and thrombosis in patients with rheumatic disorders (183), however, remains to be established.

Platelet activation also occurs in the presence of complement components (184) providing a possible explanation for the high concentrations of platelet MVs in diseases where complement-mediated platelet activation occurs, such as paroxysmal nocturnal hemoglobinuria and aplastic anemia (185). This may indeed explain why therapy with eculizumab, a humanized monoclonal antibody acting as a terminal complement inhibitor, prevents thrombosis in patients with paroxysmal nocturnal hemoglobinuria (186). Hence, with their procoagulant potential, platelet MVs may play their part in venous and arterial thrombosis. Indeed, platelet MVs were demonstrated to play an important role in atherothrombotic process. Beyond being markers of platelet activation, platelet MVs in blood showed functional effects on atherothrombotic disease because they enhanced platelet and fibrin deposition on atherosclerotic arterial wall, promoting platelet adhesion, further recruitment of platelets and thrombus formation (187). Accordingly, elevated concentrations of platelet MVs are found in patients with acute coronary syndrome (188), transient ischemic attacks and strokes (189, 190), diabetes with atherothrombotic disease and peripheral arterial disease (191), heparin-induced thrombocytopenia with thrombosis (192), as well as myeloproliferative neoplasms (193) (**Table 2**). Platelet MVs also contribute to thrombosis in patients with hemoglobinopathies such as sickle cell disease and thalassemia (194, 195). Interestingly, in polytransfused patients with thalassemia major, the number of platelet MVs augments following splenectomy, and consistently these patients have a higher tendency to develop thrombosis (196). Thrombosis is also prevalent in cancer pathophysiology, and studies suggest that it might be due, at least in part, to platelet MVs (197), although the cancer cells themselves represent an important source of MVs (150). Hence, platelet MV levels correlate with the aggressiveness of certain neoplasias, a high level being predictive of a poor clinical outcome (193, 197, 198).

Other molecules exposed in platelet MVs, in addition to phosphatidylserine, impact hemostasis and thrombosis. For instance, platelet MVs may bear activated protein C, a recognized anticoagulant protein, and thereby have a protective effect in early sepsis (199). While platelets were reported to express TF, studies by different investigators failed to detect TF in both resting and activated platelets (150, 200-202). Monocytes, however, are a major source of TF, which is stored in an encrypted form. It is suggested that monocyte-derived MVs harbor functional decrypted TF, and that the formation of highly thrombogenic platelet MVs and monocyte MVs hybrids might explain why TF has been reported on platelet MVs (150, 200-203). Hence, P-selectin harbored by platelet MVs targets MVs to the thrombi at site of injury, and injection of MVs containing P-selectin improved the kinetics of fibrin formation and could normalize the bleeding time in a hemophilia mouse model (204, 205). Importantly, P-selectin, through binding with P-selectin glycoprotein ligand 1 (PSGL-1), recruited monocyte-derived MVs expressing TF to the thrombus, and further amplified thrombosis (204, 205).

Whereas most studies on platelet MVs implicate the study of blood, platelet MVs are found in lymph and in the synovial fluid of patients with rheumatoid arthritis (175, 206, 207), suggesting that they can reach locations outside blood vessels. While platelet MVs might display a local pro-inflammatory activity through their cytokine content, exposure of autoantigens and interactions with neutrophils (173, 175, 208), platelet MVs also deliver anti-inflammatory signals by the inhibition of IL-17 and IFN-gamma production by a particular set of regulatory T cells (209), reportedly present in rheumatoid arthritis (210), thereby enhancing the stability of the regulatory T cells in an inflammatory environment (209). It is not completely understood how platelet MVs egress the

vasculature, but it might implicate transportation by leukocytes and vascular permeability (211). Hence, *in vivo* studies revealed gaps in the arthritic joint vasculature that permitted the accumulation of synthetic submicron microspheres outside blood vessels, pointing to a role of permeability in the process (211).

Constitutive platelet activation, such as seen in Stormorken's syndrome, also called "inverse Scott's syndrome", leads to thrombocytopenia and bleeding tendencies (212). Platelets from Stormorken's syndrome patients are in an activated state and therefore display PS on the outer surface due to a gain-of-function mutation in the sensing protein stromal interaction molecule 1 gene or a loss-of-function mutation of the gene coding for the calcium channel pore-forming protein ORAI1 (213, 214). As circulating platelet MVs are elevated in this pathology, it suggests, however, that platelet MVs might not suffice to prevent bleedings in this condition (212).

6.3 Conclusion

Platelet MVs contain and elaborate cargo, which can be transferred to recipient cells, thus suggesting that platelet MVs might be implicated in development, angiogenesis, wound healing, tissue regeneration and repair and remodelling, as well as cancer (169, 215-217). Continuous research on the topic and improvement of the detection methods will reveal the different roles that platelet MVs might play in health and diseases.

7. Leukocyte microvesicles

Leukocyte MVs have been shown to express adhesion molecules PSGL-1, CD11b, ICAM-1) (63, 116, 218), IL-1 β (219), tissue factor (220) and complement receptor 3 (221). In addition to containing IL-1 β , MVs also carry active caspase 1 (222), an enzyme member of the inflammasome machinery needed to cleave proIL-1 β and proIL-18 into their bioactive secreted forms. These inflammasome containing vesicles were shown to also mediate apoptotic cell death. EVs released by membrane budding of leukocytes are present in high amounts locally in inflamed tissues, and detected in the circulation. Immune cell activation, massive leukocyte death or lympho-proliferative processes have direct effects on the abundance of leukocyte-derived MVs. One general feature of circulating leukocyte-derived MVs is that their numbers in the circulation vary in broad ranges. This can reflect the ability of the triggered immune system to alter the number of its immune cells very dynamically depending on the innate and adaptive activating or suppressing signals. In line with this, the number of leukocyte-derived MVs is substantially elevated in haematological malignancies (223-225), after severe trauma (226) and in sepsis (227, 228). In addition, levels of circulating leukocytes-derived MVs increase with the presence of cardiovascular risk factors and in patients with atherosclerotic vascular diseases (**Table 2**).

As for platelets (4), accumulating evidence supports molecular and functional heterogeneity of leukocyte-derived MVs (221, 229, 230). However, the scale and significance of leukocyte-derived MV diversity is probably underestimated, warranting further investigation. While cluster of differentiation antigens provide crucial information about the cellular origin of the MVs, currently no tools to distinguish between activation- and apoptosis-induced leukocyte MVs are available. Whether externalized PS on the surface of MVs is a specific indicator of apoptotic cell origin has not been definitively demonstrated.

7.1 Regulation of leukocyte MV production

Leukocyte activation is usually associated with increased cytoplasmic calcium levels. For example, the engagement of antigen-specific receptors (T cell receptor and B cell receptor) on lymphocytes, Fc gamma receptors on natural killer cells and mast cells, and cytokine and co-stimulatory receptors results in increased cytosolic calcium ion concentrations (231) (**Figure 5**). *In vitro* leukocyte-derived MV release can be triggered by the calcium ionophore A23187 (232). Calcium signaling in immune cells is crucial for controlling a wide array of adaptive cell responses including proliferation, differentiation and various effector functions (e.g. cytokine production); this list can be extended to "vesiculation" (i.e. MV release) as a process in the case of which elevated cytosolic calcium level is a major trigger (233-235)(also discussed in section 2 of this article). Under pro-inflammatory conditions (e.g. during infection or autoimmune diseases), immune cell activation is associated with a leukocyte-derived MV release. Importantly, in the extracellular space, the released MVs are present in concomitance with soluble pro-inflammatory mediators (e.g. cytokines), and thus, they can have combined effects on cells (**Figure 5**). Indeed, T-cell derived MV-s were shown to synergize with TNF in inducing IL-8 expression by monocytes (236). The combined effects of different MVs with i) other EV subpopulations and/or ii) with soluble mediators are currently largely unexplored.

7.2 Role of leukocyte MV in inflammation

Inflammatory disease lesions are often hypoxic (232). Given that hypoxia is a known inducer of MV release (237), it may also contribute to the overall, pro-inflammatory condition-related induction of leukocyte-derived MV release. The released MVs in turn may amplify the inflammatory processes affecting different tissues (238). This is clearly exemplified during sepsis (a systemic inflammation) that leads to increased levels of circulating MVs released by granulocytes (227, 228). Due to their inherent heterogeneity overviewed recently (239), besides exerting pro-inflammatory effects on cells such as inducing cyclooxygenase 2, NF- κ B or inducible NO synthase (240-243), MVs can also play regulatory/anti-inflammatory roles as well (244-248).

7.3 Evidence for leukocyte MVs in disease

Important evidence linking presence of leukocyte-derived MVs and disease *in vivo* comes from a study in which MVs were studied in plaque and plasma of 26 patients undergoing carotid endarterectomy. Atherosclerotic plaques contained MVs predominantly released by leukocytes (macrophages, lymphocytes and granulocytes) while in contrast platelet-derived MVs were found in plasma of the same patients (140). Further evidence connecting leukocyte-derived MVs with disease is that stable statin-treated heterozygous familial hypercholesterolemia patients were found to have elevated numbers of lymphocyte- and monocyte-derived MVs. In addition, circulating MVs positive for T lymphocyte antigen determinants have been identified as markers of lipid-rich atherosclerotic plaques in familial hypercholesterolemia (249) (**Table 2**). Accordingly, patients with high-grade carotid stenosis presented with high levels of leukocyte MVs (250) and a characteristic circulating leukocyte MV-signature containing lymphocytes, monocytes and activation markers (CD66b) in the systemic circulation reflected the formation of coronary thrombotic occlusions in patients with acute myocardial infarction (13), to whom monocyte MVs related to the long-term prognosis of cardiovascular death (251). Moreover, in a recent prospective 5-year follow-up randomized, controlled, multicenter study, T lymphocyte-derived circulating MVs were

found to be elevated in high cardiovascular risk subjects without clinical atherosclerosis who had a major cardiovascular event during the 5 year follow up period (252) (**Table 2**). Finally, the role of leukocyte-derived MVs is further supported by the observation that circulating leukocyte-derived MVs are predictors of subclinical atherosclerosis burden in asymptomatic individuals (253) (**Table 2**). Altogether, these findings suggest that leukocyte MV shedding relates to atherosclerotic CVD progression, providing a link between inflammation and thrombosis.

7.3 Lymphocyte MVs

Apoptosis is associated with the release of MVs (254), and atherosclerotic plaques have been reported to be enriched in apoptotic lymphocytes (255). Hence, lymphocyte MVs have been detected in atherosclerotic plaques (256). Furthermore, circulating T lymphocyte-derived MVs are elevated in familial hypercholesterolemia patients (249). Thus, the link between lymphocyte derived-MVs and atherosclerosis is supported by numerous reports. T cell-derived MVs were shown to impair endothelial function (257). On the other hand, vascular hyperreactivity was also documented and lymphocyte-derived MVs were shown to inhibit angiogenesis (258). The LDL receptor has been proposed to mediate the uptake of T cell-derived MVs and influence the VEGF pathway (259).

Also, data suggest a link between lymphocyte-derived MVs and preeclampsia. In preeclamptic women T cell- and granulocyte-derived MVs were increased compared with normal pregnancy (235). Furthermore, synovial fluid CD8+ T cell-derived MV profiles were found to be characteristic for rheumatoid arthritis (206) suggesting that leukocyte MVs may potentially hint at locally activated immune cell populations.

Surprisingly, there are very few reports published on circulating B cell-derived MVs, mainly related to B cell malignancies (224, 260-262).

7.5 Conclusion

MVs derived from leukocytes can play effector roles in the pathophysiological mechanisms of different diseases. Recent advances in immunology have identified high number of immune cell subsets. From the MV research perspective, MVs secreted by these immune cell subsets, represent a highly promising, however, yet minimally explored area of research that deserves further attention.

8 Red blood cell microvesicles

RBCs are 700,000 to 5.2 million to a microliter of blood. Any stimulus of RBC vesiculation, such as calcium influx and spicule extension (263-270), may thus trigger a significant storm of RBC-derived MVs (271). Indeed, RBC MVs are amongst the most common circulating vesicles, and they are particularly elevated during intravascular hemolysis, in ST-segment elevation myocardial infarction (272, 273) related to myocardial damage (273), in sickle cell disease (50, 274-277), thalassemia (277-279) and during blood pocket storage and aging (280-283), among others. RBCs are also thought to release MVs spontaneously during reticulocyte maturation (284) and upon plasmodium falciparum replication (285).

RBC-derived MVs display many characteristics and activities common to other MVs, including externalization of PS, with subsequent pro-coagulant effects (50, 279, 286-288), complement pathway activation (289) and a pro-inflammatory impact on blood

vessels (290). RBC-derived MVs, like their mother cells, are also unique due to the quantity of iron that they carry. Each RBC contains about 250 million molecules of hemoglobin, each with 4 prosthetic haeme groups and 4 iron ions. Leakage of hemoglobin out of only 0.1% RBC results in an increase up to 2 μM in plasma hemoglobin. These significant concentrations of hemoglobin attracted attention with respect to vesiculation during intravascular hemolysis.

One relevant question relates to the retention of hemoglobin, haeme and iron by MVs during RBC vesiculation and hemolysis. MV depletion experiments using differential centrifugation or size fractionation of plasma suggest that 5% to 40% of extracellular hemoglobin associates with RBC membrane fragments during sickle cell disease (291), thalassemia (279) and blood aging (281). *Hemolysis*, as defined today, is thus likely to comprise vesiculation as a mode of hemoglobin exit from RBC and a mode of presentation in plasma, beyond haeme association with classical partners such as hemopexin, haptoglobin, albumin and LDL.

A second question pertains to the redox state of MV-contained hemoglobin, haeme and iron. The pseudoperoxidase activity of these molecules is linked to the level of enzymatic control applied by porphyrins and globins onto the iron atoms. This may prove critical to the pathophysiological impact of RBC-derived MV. Healthy MVs may contain mostly intact hemoglobin, like inert RBCs. Pathological RBC MVs may contain excess haeme and trigger radical oxygen species production by vascular endothelial cells through TLR-4 signaling, like in sickle cell disease (291, 292).

Early biochemical analyses suggested that hemoglobin remains functional and able to exchange gases, judging by the NO-depleting and vaso-constrictive effects of RBC MV (281, 283, 291, 293). RBC MVs may contain a significant proportion of meth-hemoglobin (291), an oxidized metabolite prone to releasing free haeme. When RBC vesiculation is coupled to hemoglobin injury, MV may transport lipophilic, protein-free haeme (**Figure 6**). This association would prove deleterious, as haeme embedded into membrane phospholipids is known to release iron and catalyze extensive oxidative degradation of nearby lipids and proteins. RBC MVs may thus sequester haeme away from classical recycling pathways, and mediate unique effects through a mixed load of haeme and lipid metabolites.

9. Limitations and future directions

During their formation process, MVs retain functional receptors, proteins, bioactive lipids, organelles and genetic material from the parental cells, and behave as active sensors, communicators, and effectors on their surrounding environment. There are a number of important points that need to be considered when designing and analysing experiments to investigate the presence and function of MVs:

- Numerous pitfalls could occur during their isolation procedure and their characterization, such as the presence of contaminating protein. Therefore, one should rely on *at least* two different technical approaches to identify them, with consideration given to the limitations of each approach. We should also bear in mind that pharmacological interventions in patients can modulate MV circulating levels, either directly or indirectly.
- As highlighted in this review, there is an emerging role for MVs in vascular homeostasis and disease. However, further research is needed to pin down the

molecular mechanisms involved to further elucidate MVs potential as therapeutic targets or vectors.

- To accelerate the progress with biomarker discovery, we need to enhance our understanding of the biological role played by specific cell derived MVs in haemostasis. For example, understanding the role of EMVs in vascular inflammation will enable routine quantification of EMVs in patients' samples to be interpreted in a more meaningful manner.
- MVs, and more generally extracellular vesicles, are becoming an intense area of research as therapeutic targets in heart diseases. In addition, improved characterisation of their content and surface molecule expression will aid in integrating information regarding their function in normal physiology with their pathological role.

Central to the above is the optimisation and standardisation of isolation and analysis of MVs and the use of robust experimental controls.

Table 1: Measuring the efficiency of MV isolation procedures.

Starting material, for example plasma or conditioned cell culture medium, will contain MVs, proteins and lipoproteins. To determine the recovery of MVs, measure MVs before (starting material) and after isolation, and express the recovery as $[\text{concentration isolated MV}]/[\text{concentration MVs in starting material}] \times 100\%$. Confirm the identity of MVs in obtained fraction(s) by electron microscopy. Finally, to determine the (relative) enrichment of isolated MVs compared to the starting material, measure the concentration of protein and lipoprotein before and after isolation, and calculate the ratio of $[\text{MV concentration}]/[\text{protein concentration}]$ and $[\text{MV concentration}]/[\text{lipoprotein concentration}]$.

*MVs cannot be visualized directly in most fluids due to the presence of proteins and other contaminants.

		Starting material	Isolated MV
Recovery MV	Measure MV	+	+
Confirm MV identity	Electron Microscopy	N/A*	+
Contamination	Measure protein Measure lipoprotein	+	+
		+	+
Enrichment of MV	EV/protein ratio EV/lipoprotein ratio	+	+
		+	+

Table 2 : Plasma MV changes in subjects with cardiovascular risk factors and in patients with atherosclerotic vascular diseases. CVD: cardiovascular diseases; TF: tissue factor; PS+ MVs: MVs expressing phosphatidylserine; ND : Not determined.

		MV sub-population	changes	references
Cardiovascular risk factors	Age	Endothelial, TF+MV, PS+MV	↑,↓	(294, 295)
	Female gender	Endothelial, Platelet, PS+MV	↑	(296)
	Hypertension	Endothelial, platelet	↑	(297, 298)
	Hypercholesterolemia	Endothelial, lymphocyte, leucocyte, platelet	↑	(249, 299)
	Hypertriglyceridemia	Endothelial	↑	(298, 300)
	Smoking, Pollution	Endothelial, platelet, leucocyte	↑	(148, 301-303)
	Obesity	Endothelial, platelet	↑	(304-307)
	Diabetes	Endothelial, platelet, leucocyte, TF+MV	↑	(308-310)
	Metabolic syndrome	Endothelial	↑	(298, 311)
	Family history CVD	ND	ND	ND
	Physical inactivity	Endothelial	↑	(312)
Atherosclerotic vascular diseases	Subclinical atherosclerosis	Leucocyte, platelet, lymphocyte, endothelial	↑	(249, 253, 299, 313)
	Coronary calcification	Endothelial, Platelet	↑	(314)
	Acute coronary syndrome	Endothelial, Platelet, monocyte	↑	(13, 310, 315-319)
	Stable coronary disease	Endothelial, Platelet	↑	(316, 320)
	Cardiac sudden death	Endothelial	↑	(321)
	Acute stroke	Endothelial, platelet, leukocyte	↑ or no change	(189, 322-324)
	Cerebrovascular atherosclerosis	Endothelial	↑	(325)
	Peripheral artery disease	Platelet	↑	(326-328)
	End-stage renal disease	Endothelial, platelet, erythrocyte	↑	(329, 330)

Figure 1: Floppase activity and facilitated transport of phosphatidylserine by TMEM-16 F (ANO-6) and procoagulant MV shedding.

At rest, phosphatidylserine (PS) is translocated to the inner leaflet by flippase activity. Right panel: Upon cell activation and calcium-dependent flippase inhibition, PS translocation to the outer leaflet is driven by TMEM-16F (yellow shape) and local K^+ efflux prompts cell shrinkage and re-shaping. High calcium concentration promoted by Stored Operated Channels (SOCE) favours the constitution of TMEM16-F platforms by oligomerization or interaction with other receptors like P_{2XR} in the case of long term exposure to Ca^{2+} (green shape). Transient phospholipid imbalance between leaflets and the proteolysis of cytoskeleton by calpains and/or caspases lead to facilitated procoagulant MV shedding. Putative scramblase transducers as Xkr8 are activated by caspases and would trigger enhanced floppase activity as described in apoptotic cells (see text for details). Exposed PS catalyses the assembly of blood coagulation complexes at cell and MV surface (E: Enzyme, S: Substrate, CF cofactor)




Figure 1

Figure 2: Molecular component and pathways used by MVs to regulate cell communication. MVs may transfer membrane components and cytosolic and nucleic acids to the target cell by internalization or following membrane fusion. MVs interactions with membrane-associated receptors may induce specific responses in target cells. Uptake of some mediators, such as miRNA, induces reprogramming of target cells. Receptors present on MV surface could be recycled and presented on the surface of the target cell.

Figure 2




Figure 3: Biogenesis and biological effects of endothelial MVs. Endothelial MV release can be triggered following cell activation or apoptosis. The resulting remote biological effects of endothelial MVs can be either protective or deleterious. TNF α = Tumor necrosis factor alpha; LPS = lipopolysaccharide; ROS = reactive oxygen species; PAI-1 = plasminogen activator inhibitor-1; CRP = C-reactive protein; AngII = angiotensin II; oxLDL= oxidized-low density lipoprotein; ROCK-1 or -2 = Rho associated protein kinase 1 or 2; NF- κ B= nuclear factor kappa-b, TRAIL/Apo2L= TNF-related apoptosis inducing ligand; p38 MAPK= p38 mitogen-activated protein kinase; ERK 1/2 = extracellular signal-regulated kinases.

Figure 3




Figure 4: Composition of platelet-derived MVs

Platelet MVs are produced by activated platelets on disruption of membrane asymmetry and plasma membrane budding (steps 1 and 2). Although platelets are anucleated, they do contain a broad arsenal of molecules, which can be transferred to platelet MVs. Adapted from Melki et al. Platelets 2016.

Figure 4




Figure 5: Leukocyte MV formation. MV release by leukocytes is triggered by i) engagement of various cell surface receptors by activating ligands that lead to increased cytosolic calcium ion concentration as well as ii) by hypoxic environment. MVs and conventional mediators (cytokines) are present simultaneously in the extracellular space and may exert combinatorial effects on cells. A few pathological conditions with confirmed role of leukocyte-derived MVs are listed. TCR = T cell receptor; BCR = B cell receptor ; NK = natural killer cell.

Figure 6





Figure 6: Red blood cell MVs are unique transporters of haeme.

Red blood cell (RBC) release MVs under stress, probably from membrane buds called spicules. RBC MVs contain high amounts of haemoglobin originating from their parent cell cytoplasm. RBC MVs may thus transport unusually high amounts of haeme and iron, bringing these highly pro-oxidant molecules in close proximity of their target cell membranes, with a vast array of possible pathophysiological consequences, which remain to be explored.

Figure 6



References:

1. Chargaff E, West R. The biological significance of the thromboplastic protein of blood. *J Biol Chem* 1946; 166(1): 189-97.
2. Hargett LA, Bauer NN. On the origin of microparticles: From "platelet dust" to mediators of intercellular communication. *Pulm Circ* 2013; 3(2): 329-40.
3. Wolf P. The nature and significance of platelet products in human plasma. *Br J Haematol* 1967; 13(3): 269-88.
4. Boilard E, Duchez AC, Brisson A. The diversity of platelet microparticles. *Curr Opin Hematol* 2015; 22(5): 437-44.
5. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. *Blood* 1999; 94(11): 3791-9.
6. Aatonen MT, Ohman T, Nyman TA, et al. Isolation and characterization of platelet-derived extracellular vesicles. *J Extracell Vesicles* 2014; 3: 0.3402/jev.v3.24692.
7. Garcia BA, Smalley DM, Cho H, et al. The platelet microparticle proteome. *J Proteome Res* 2005; 4(5): 1516-21.
8. Peterson DB, Sander T, Kaul S, et al. Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles. *Proteomics* 2008; 8(12): 2430-46.
9. Amabile N, Heiss C, Chang V, et al. Increased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients. *J Heart Lung Transplant* 2009; 28(10): 1081-6.
10. Bakouboula B, Morel O, Faure A, et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2008; 177(5): 536-43.
11. Delabranche X, Quenot JP, Lavigne T, et al. Early Detection of Disseminated Intravascular Coagulation During Septic Shock: A Multicenter Prospective Study. *Crit Care Med* 2016; 44(10): e930-9.
12. Kurtzman N, Zhang L, French B, et al. Personalized cytomic assessment of vascular health: Evaluation of the vascular health profile in diabetes mellitus. *Cytometry B Clin Cytom* 2013; 84(4): 255-66.
13. Suades R, Padro T, Crespo J, et al. Circulating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time. *Int J Cardiol* 2016; 202: 378-87.
14. Wekesa AL, Cross KS, O'Donovan O, et al. Predicting carotid artery disease and plaque instability from cell-derived microparticles. *Eur J Vasc Endovasc Surg* 2014; 48(5): 489-95.
15. Contreras FX, Sanchez-Magraner L, Alonso A, et al. Transbilayer (flip-flop) lipid motion and lipid scrambling in membranes. *FEBS Lett* 2010; 584(9): 1779-86.
16. Awojodu AO, Keegan PM, Lane AR, et al. Acid sphingomyelinase is activated in sickle cell erythrocytes and contributes to inflammatory microparticle generation in SCD. *Blood* 2014; 124(12): 1941-50.
17. Bianco F, Perrotta C, Novellino L, et al. Acid sphingomyelinase activity triggers microparticle release from glial cells. *EMBO J* 2009; 28(8): 1043-54.

18. Bouter A, Carmeille R, Gounou C, et al. Review: Annexin-A5 and cell membrane repair. *Placenta* 2015; 36 Suppl 1: S43-9.
19. Draeger A, Babiychuk EB. Ceramide in plasma membrane repair. *Handb Exp Pharmacol* 2013(216): 341-53.
20. Nabhan JF, Hu R, Oh RS, et al. Formation and release of arrestin domain-containing protein 1-mediated microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 protein. *Proc Natl Acad Sci U S A* 2012; 109(11): 4146-51.
21. Derganc J, Antonny B, Copic A. Membrane bending: the power of protein imbalance. *Trends Biochem Sci* 2013; 38(11): 576-84.
22. Mattheij NJ, Braun A, van Kruchten R, et al. Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling, swelling, and protein cleavage. *FASEB J* 2016; 30(2): 727-37.
23. van Geffen JP, Swieringa F, Heemskerk JW. Platelets and coagulation in thrombus formation: aberrations in the Scott syndrome. *Thromb Res* 2016; 141 Suppl 2: S12-6.
24. Shi Z, Baumgart T. Dynamics and instabilities of lipid bilayer membrane shapes. *Adv Colloid Interface Sci* 2014; 208: 76-88.
25. Bevers EM, Williamson PL. Getting to the Outer Leaflet: Physiology of Phosphatidylserine Exposure at the Plasma Membrane. *Physiol Rev* 2016; 96(2): 605-45.
26. Coleman JA, Quazi F, Molday RS. Mammalian P4-ATPases and ABC transporters and their role in phospholipid transport. *Biochim Biophys Acta* 2013; 1831(3): 555-74.
27. Wolfs JL, Comfurius P, Rasmussen JT, et al. Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction. *Cell Mol Life Sci* 2005; 62(13): 1514-25.
28. Basse F, Gaffet P, Rendu F, et al. Translocation of spin-labeled phospholipids through plasma membrane during thrombin- and ionophore A23187-induced platelet activation. *Biochemistry* 1993; 32(9): 2337-44.
29. Smeets EF, Comfurius P, Bevers EM, et al. Calcium-induced transbilayer scrambling of fluorescent phospholipid analogs in platelets and erythrocytes. *Biochim Biophys Acta* 1994; 1195(2): 281-6.
30. Morel O, Jesel L, Freyssinet JM, et al. Cellular mechanisms underlying the formation of circulating microparticles. *Arterioscler Thromb Vasc Biol* 2011; 31(1): 15-26.
31. Kunzelmann-Marche C, Freyssinet JM, Martinez MC. Loss of plasma membrane phospholipid asymmetry requires raft integrity. Role of transient receptor potential channels and ERK pathway. *J Biol Chem* 2002; 277(22): 19876-81.
32. del Conde I, Nabi F, Tonda R, et al. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. *Arterioscler Thromb Vasc Biol* 2005; 25(5): 1065-70.
33. Fujii T, Sakata A, Nishimura S, et al. TMEM16F is required for phosphatidylserine exposure and microparticle release in activated mouse platelets. *Proc Natl Acad Sci U S A* 2015; 112(41): 12800-5.
34. Lhermusier T, Chap H, Payrastre B. Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome. *J Thromb Haemost* 2011; 9(10): 1883-91.
35. Yu K, Whitlock JM, Lee K, et al. Identification of a lipid scrambling domain in ANO6/TMEM16F. *Elife* 2015; 4: e06901.
36. Yang H, Kim A, David T, et al. TMEM16F forms a Ca²⁺-activated cation channel required for lipid scrambling in platelets during blood coagulation. *Cell* 2012; 151(1): 111-22.

37. Bevers EM, Williamson PL. Phospholipid scramblase: an update. *FEBS Lett* 2010; 584(13): 2724-30.
38. Brooks MB, Catalfamo JL, Friese P, et al. Scott syndrome dogs have impaired coated-platelet formation and calcein-release but normal mitochondrial depolarization. *J Thromb Haemost* 2007; 5(9): 1972-4.
39. Brooks MB, Catalfamo JL, Etter K, et al. Exclusion of ABCA-1 as a candidate gene for canine Scott syndrome. *J Thromb Haemost* 2008; 6(9): 1608-10.
40. Weiss HJ. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. *Semin Thromb Hemost* 2009; 35(2): 233-41.
41. Toti F, Satta N, Fressinaud E, et al. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. *Blood* 1996; 87(4): 1409-15.
42. Williamson P, Christie A, Kohlin T, et al. Phospholipid scramblase activation pathways in lymphocytes. *Biochemistry* 2001; 40(27): 8065-72.
43. Gidon-Jeangirard C, Hugel B, Holl V, et al. Annexin V delays apoptosis while exerting an external constraint preventing the release of CD4+ and PrPc+ membrane particles in a human T lymphocyte model. *J Immunol* 1999; 162(10): 5712-8.
44. Stampfuss JJ, Censarek P, Fischer JW, et al. Complete downmodulation of P-selectin glycoprotein ligand in monocytes undergoing apoptosis. *Arterioscler Thromb Vasc Biol* 2008; 28(7): 1375-8.
45. Baj-Krzyworzeka M, Majka M, Pratico D, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. *Exp Hematol* 2002; 30(5): 450-9.
46. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. *Thromb Res* 2003; 109(4): 175-80.
47. Milioli M, Ibanez-Vea M, Sidoli S, et al. Quantitative proteomics analysis of platelet-derived microparticles reveals distinct protein signatures when stimulated by different physiological agonists. *J Proteomics* 2015; 121: 56-66.
48. Connor DE, Exner T, Ma DD, et al. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. *Thromb Haemost* 2010; 103(5): 1044-52.
49. Arraud N, Linares R, Tan S, et al. Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. *J Thromb Haemost* 2014; 12(5): 614-27.
50. Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. *Blood* 2003; 102(7): 2678-83.
51. Key NS. Analysis of tissue factor positive microparticles. *Thromb Res* 2010; 125 Suppl 1: S42-5.
52. Rautou PE, Mackman N. Deletion of microvesicles from the circulation. *Circulation* 2012; 125(13): 1601-4.
53. Montoro-Garcia S, Shantsila E, Orenes-Pinero E, et al. An innovative flow cytometric approach for small-size platelet microparticles: influence of calcium. *Thromb Haemost* 2012; 108(2): 373-83.
54. Freyssinet JM, Toti F. Membrane microparticle determination: at least seeing what's being sized! *J Thromb Haemost* 2010; 8(2): 311-4.

55. Dasgupta SK, Abdel-Monem H, Niravath P, et al. Lactadherin and clearance of platelet-derived microvesicles. *Blood* 2009; 113(6): 1332-9.
56. Gyorgy B, Modos K, Pallinger E, et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. *Blood* 2011; 117(4): e39-48.
57. Lacroix R, Judicone C, Poncelet P, et al. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. *J Thromb Haemost* 2012; 10(3): 437-46.
58. Darabi M, Kontush A. Phosphatidylserine in atherosclerosis. *Curr Opin Lipidol* 2016; 27(4): 414-20.
59. Cauwenberghs S, Feijge MA, Harper AG, et al. Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilization of actin cytoskeleton. *FEBS Lett* 2006; 580(22): 5313-20.
60. Flaumenhaft R, Dilks JR, Richardson J, et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. *Blood* 2009; 113(5): 1112-21.
61. Shcherbina A, Kenney DM, Bretscher A, et al. Dynamic association of moesin with the membrane skeleton of thrombin- activated platelets. *Blood* 1999; 93(6): 2128-9.
62. Fox JE, Austin CD, Reynolds CC, et al. Evidence that agonist-induced activation of calpain causes the shedding of procoagulant-containing microvesicles from the membrane of aggregating platelets. *J Biol Chem* 1991; 266(20): 13289-95.
63. Nolan S, Dixon R, Norman K, et al. Nitric oxide regulates neutrophil migration through microparticle formation. *Am J Pathol* 2008; 172(1): 265-73.
64. Sebbagh M, Hamelin J, Bertoglio J, et al. Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. *J Exp Med* 2005; 201(3): 465-71.
65. Sebbagh M, Renvoize C, Hamelin J, et al. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. *Nat Cell Biol* 2001; 3(4): 346-52.
66. Sapet C, Simoncini S, Lloriod B, et al. Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. *Blood* 2006; 108(6): 1868-76.
67. Tramontano AF, O'Leary J, Black AD, et al. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. *Biochem Biophys Res Commun* 2004; 320(1): 34-8.
68. Vion AC, Ramkhalawon B, Loyer X, et al. Shear stress regulates endothelial microparticle release. *Circ Res* 2013; 112(10): 1323-33.
69. Midura EF, Prakash PS, Johnson BL, 3rd, et al. Impact of caspase-8 and PKA in regulating neutrophil-derived microparticle generation. *Biochem Biophys Res Commun* 2016; 469(4): 917-22.
70. Wang T, Gilkes DM, Takano N, et al. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. *Proc Natl Acad Sci U S A* 2014; 111(31): E3234-42.
71. Muralidharan-Chari V, Clancy J, Plou C, et al. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. *Curr Biol* 2009; 19(22): 1875-85.
72. Suzuki J, Denning DP, Imanishi E, et al. Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. *Science* 2013; 341(6144): 403-6.

73. Zhu L, Wang K, Cui J, et al. Label-free quantitative detection of tumor-derived exosomes through surface plasmon resonance imaging. *Anal Chem* 2014; 86(17): 8857-64.
74. Pugholm LH, Revenfeld AL, Sondergaard EK, et al. Antibody-Based Assays for Phenotyping of Extracellular Vesicles. *Biomed Res Int* 2015; 2015: 524817.
75. van der Pol E, Coumans FA, Grootemaat AE, et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. *J Thromb Haemost* 2014; 12(7): 1182-92.
76. Lacroix R, Robert S, Poncelet P, et al. Overcoming limitations of microparticle measurement by flow cytometry. *Semin Thromb Hemost* 2010; 36(8): 807-18.
77. Lacroix R, Robert S, Sabatier F, et al. Flow cytometry. In: *Extracellular vesicles in health and disease*. Pan Stanford Publishing 2014; pp. 201-22.
78. Robert S, Lacroix R, Poncelet P, et al. High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles--brief report. *Arterioscler Thromb Vasc Biol* 2012; 32(4): 1054-8.
79. Hoen EN, van der Vlist EJ, Aalberts M, et al. Quantitative and qualitative flow cytometric analysis of nanosized cell-derived membrane vesicles. *Nanomedicine* 2011; 8(5): 712-20.
80. Zhu S, Ma L, Wang S, et al. Light-scattering detection below the level of single fluorescent molecules for high-resolution characterization of functional nanoparticles. *ACS Nano* 2014; 8(10): 10998-1006.
81. van der Pol E, Boing AN, Gool EL, et al. Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. *J Thromb Haemost* 2016; 14(1): 48-56.
82. van der Pol E, Coumans FA, Sturk A, et al. Refractive index determination of nanoparticles in suspension using nanoparticle tracking analysis. *Nano Lett* 2014; 14(11): 6195-201.
83. Poncelet P, Robert S, Bailly N, et al. Tips and tricks for flow cytometry-based analysis and counting of microparticles. *Transfus Apher Sci* 2015; 53(2): 110-26.
84. Sodar BW, Kittel A, Paloczi K, et al. Low-density lipoprotein mimics blood plasma-derived exosomes and microvesicles during isolation and detection. *Sci Rep* 2016; 6: 24316.
85. Amabile N, Renard JM, Caussin C, et al. Circulating immune complexes do not affect microparticle flow cytometry analysis in acute coronary syndrome. *Blood* 2012; 119(9): 2174-5; author reply 5-6.
86. Dragovic RA, Gardiner C, Brooks AS, et al. Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. *Nanomedicine* 2011; 7(6): 780-8.
87. Coumans FA, van der Pol E, Boing AN, et al. Reproducible extracellular vesicle size and concentration determination with tunable resistive pulse sensing. *J Extracell Vesicles* 2014; 3: 25922.
88. Lotvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. *J Extracell Vesicles* 2014; 3: 26913.
89. Poncelet P, Robert S, Bouriche T, et al. Standardized counting of circulating platelet microparticles using currently available flow cytometers and scatter-based triggering: Forward or side scatter? *Cytometry A* 2016; 89(2): 148-58.
90. Nolan JP. Flow Cytometry of Extracellular Vesicles: Potential, Pitfalls, and Prospects. *Curr Protoc Cytom* 2015; 73: 13 4 1- 4 6.

91. Yuana Y, Boing AN, Grootemaat AE, et al. Handling and storage of human body fluids for analysis of extracellular vesicles. *J Extracell Vesicles* 2015; 4: 10.3402/jev.v4.29260.
92. Boing AN, van der Pol E, Grootemaat AE, et al. Single-step isolation of extracellular vesicles by size-exclusion chromatography. *J Extracell Vesicles* 2014; 3: 10.3402/jev.v3.23430.
93. Witwer KW, Buzas EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. *J Extracell Vesicles* 2013; 2: doi: 10.3402/jev.v2i0.20360.
94. Lacroix R, Sabatier F, Mialhe A, et al. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. *Blood* 2007; 110(7): 2432-9.
95. Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. *J Exp Med* 1996; 183(3): 1161-72.
96. Morel O, Toti F, Hugel B, et al. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. *Curr Opin Hematol* 2004; 11(3): 156-64.
97. Ratajczak J, Wysoczynski M, Hayek F, et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. *Leukemia* 2006; 20(9): 1487-95.
98. Barry OP, Pratico D, Lawson JA, et al. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. *J Clin Invest* 1997; 99(9): 2118-27.
99. Barry OP, Kazanietz MG, Pratico D, et al. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. *J Biol Chem* 1999; 274(11): 7545-56.
100. Zomer A, Steenbeek SC, Maynard C, et al. Studying extracellular vesicle transfer by a Cre-loxP method. *Nat Protoc* 2016; 11(1): 87-101.
101. Svensson KJ, Christianson HC, Wittrup A, et al. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1. *J Biol Chem* 2013; 288(24): 17713-24.
102. Feng D, Zhao WL, Ye YY, et al. Cellular internalization of exosomes occurs through phagocytosis. *Traffic* 2010; 11(5): 675-87.
103. Parolini I, Federici C, Raggi C, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. *J Biol Chem* 2009; 284(49): 34211-22.
104. Kanada M, Bachmann MH, Hardy JW, et al. Differential fates of biomolecules delivered to target cells via extracellular vesicles. *Proc Natl Acad Sci U S A* 2015; 112(12): E1433-42.
105. Al Faraj A, Gazeau F, Wilhelm C, et al. Endothelial cell-derived microparticles loaded with iron oxide nanoparticles: feasibility of MR imaging monitoring in mice. *Radiology* 2012; 263(1): 169-78.
106. Dasgupta SK, Le A, Chavakis T, et al. Developmental endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the endothelium. *Circulation* 2012; 125(13): 1664-72.
107. Willekens FL, Werre JM, Kruijt JK, et al. Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors. *Blood* 2005; 105(5): 2141-5.

108. Jansen F, Yang X, Hoyer FF, et al. Endothelial microparticle uptake in target cells is annexin I/phosphatidylserine receptor dependent and prevents apoptosis. *Arterioscler Thromb Vasc Biol* 2012; 32(8): 1925-35.
109. Terrisse AD, Puech N, Allart S, et al. Internalization of microparticles by endothelial cells promotes platelet/endothelial cell interaction under flow. *J Thromb Haemost* 2010; 8(12): 2810-9.
110. Happonen KE, Tran S, Morgelin M, et al. The Gas6-Axl Protein Interaction Mediates Endothelial Uptake of Platelet Microparticles. *J Biol Chem* 2016; 291(20): 10586-601.
111. Faille D, El-Assaad F, Mitchell AJ, et al. Endocytosis and intracellular processing of platelet microparticles by brain endothelial cells. *J Cell Mol Med* 2012; 16(8): 1731-8.
112. Alexy T, Rooney K, Weber M, et al. TNF-alpha alters the release and transfer of microparticle-encapsulated miRNAs from endothelial cells. *Physiol Genomics* 2014; 46(22): 833-40.
113. Leroyer AS, Rautou PE, Silvestre JS, et al. CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. *J Am Coll Cardiol* 2008; 52(16): 1302-11.
114. Barry OP, Pratico D, Savani RC, et al. Modulation of monocyte-endothelial cell interactions by platelet microparticles. *J Clin Invest* 1998; 102(1): 136-44.
115. Mause SF, von Hundelshausen P, Zerneck A, et al. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. *Arterioscler Thromb Vasc Biol* 2005; 25(7): 1512-8.
116. Rautou PE, Leroyer AS, Ramkhalawon B, et al. Microparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. *Circ Res* 2011; 108(3): 335-43.
117. Ratajczak J, Miekus K, Kucia M, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. *Leukemia* 2006; 20(5): 847-56.
118. Batagov AO, Kurochkin IV. Exosomes secreted by human cells transport largely mRNA fragments that are enriched in the 3'-untranslated regions. *Biol Direct* 2013; 8: 12.
119. Huang X, Yuan T, Tschannen M, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. *BMC Genomics* 2013; 14: 319.
120. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. *Nat Commun* 2011; 2: 282.
121. Zerneck A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci Signal* 2009; 2(100): ra81.
122. Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. *Nucleic Acids Res* 2012; 40(21): 10937-49.
123. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. *PLoS One* 2008; 3(11): e3694.
124. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 2007; 9(6): 654-9.
125. Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci U S A* 2011; 108(12): 5003-8.

126. Jeppesen DK, Nawrocki A, Jensen SG, et al. Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors. *Proteomics* 2014; 14(6): 699-712.
127. Li L, Zhu D, Huang L, et al. Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. *PLoS One* 2012; 7(10): e46957.
128. Melo SA, Sugimoto H, O'Connell JT, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. *Cancer Cell* 2014; 26(5): 707-21.
129. Jansen F, Yang X, Hoelscher M, et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. *Circulation* 2013; 128(18): 2026-38.
130. Caporali A, Meloni M, Nailor A, et al. p75(NTR)-dependent activation of NF-kappaB regulates microRNA-503 transcription and pericyte-endothelial crosstalk in diabetes after limb ischaemia. *Nat Commun* 2015; 6: 8024.
131. Hergenreider E, Heydt S, Treguer K, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. *Nat Cell Biol* 2012; 14(3): 249-56.
132. Finn NA, Eapen D, Manocha P, et al. Coronary heart disease alters intercellular communication by modifying microparticle-mediated microRNA transport. *FEBS Lett* 2013; 587(21): 3456-63.
133. Sabatier F, Camoin-Jau L, Anfosso F, et al. Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. *J Cell Mol Med* 2009; 13(3): 454-71.
134. Loyer X, Vion AC, Tedgui A, et al. Microvesicles as cell-cell messengers in cardiovascular diseases. *Circ Res* 2014; 114(2): 345-53.
135. Cunningham M, Marks N, Barnado A, et al. Are microparticles the missing link between thrombosis and autoimmune diseases? Involvement in selected rheumatologic diseases. *Semin Thromb Hemost* 2014; 40(6): 675-81.
136. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. *Arterioscler Thromb Vasc Biol* 2011; 31(1): 27-33.
137. Combes V, Simon AC, Grau GE, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. *J Clin Invest* 1999; 104(1): 93-102.
138. Thomas GM, Panicot-Dubois L, Lacroix R, et al. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. *J Exp Med* 2009; 206(9): 1913-27.
139. Chahed S, Leroyer AS, Benzerroug M, et al. Increased vitreous shedding of microparticles in proliferative diabetic retinopathy stimulates endothelial proliferation. *Diabetes* 2010; 59(3): 694-701.
140. Leroyer AS, Isobe H, Leseche G, et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. *J Am Coll Cardiol* 2007; 49(7): 772-7.
141. Szotowski B, Antoniuk S, Goldin-Lang P, et al. Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells. *Cardiovasc Res* 2007; 73(4): 806-12.
142. Brodsky SV, Malinowski K, Golightly M, et al. Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. *Circulation* 2002; 106(18): 2372-8.

143. Simak J, Holada K, Vostal JG. Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin. *BMC Cell Biol* 2002; 3: 11.
144. Wang JM, Wang Y, Huang JY, et al. C-Reactive protein-induced endothelial microparticle generation in HUVECs is related to BH4-dependent NO formation. *J Vasc Res* 2007; 44(3): 241-8.
145. Faure V, Dou L, Sabatier F, et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. *J Thromb Haemost* 2006; 4(3): 566-73.
146. Nomura S, Shouzu A, Omoto S, et al. Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes. *Clin Appl Thromb Hemost* 2004; 10(3): 205-15.
147. Jenkins NT, Padilla J, Boyle LJ, et al. Disturbed blood flow acutely induces activation and apoptosis of the human vascular endothelium. *Hypertension* 2013; 61(3): 615-21.
148. Heiss C, Amabile N, Lee AC, et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production. *J Am Coll Cardiol* 2008; 51(18): 1760-71.
149. Simoncini S, Njock MS, Robert S, et al. TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation. *Circ Res* 2009; 104(8): 943-51.
150. Owens AP, 3rd, Mackman N. Microparticles in hemostasis and thrombosis. *Circ Res* 2011; 108(10): 1284-97.
151. Kagawa H, Komiyama Y, Nakamura S, et al. Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells. *Thromb Res* 1998; 91(6): 297-304.
152. Sabatier F, Roux V, Anfosso F, et al. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. *Blood* 2002; 99(11): 3962-70.
153. Abid Hussein MN, Boing AN, Biro E, et al. Phospholipid composition of in vitro endothelial microparticles and their in vivo thrombogenic properties. *Thromb Res* 2008; 121(6): 865-71.
154. Pawlinski R, Wang JG, Owens AP, 3rd, et al. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. *Blood* 2010; 116(5): 806-14.
155. Aras O, Shet A, Bach RR, et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. *Blood* 2004; 103(12): 4545-53.
156. Shet A, Kaplan EL, Johnson DR, et al. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. *J Infect Dis* 2003; 188(6): 809-17.
157. Mostefai HA, Meziani F, Mastronardi ML, et al. Circulating microparticles from patients with septic shock exert protective role in vascular function. *Am J Respir Crit Care Med* 2008; 178(11): 1148-55.
158. Morel O, Toti F, Morel N, et al. Microparticles in endothelial cell and vascular homeostasis: are they really noxious? *Haematologica* 2009; 94(3): 313-7.
159. Curtis AM, Wilkinson PF, Gui M, et al. p38 mitogen-activated protein kinase targets the production of proinflammatory endothelial microparticles. *J Thromb Haemost* 2009; 7(4): 701-9.

160. Chirinos JA, Zambrano JP, Virani SS, et al. Correlation between apoptotic endothelial microparticles and serum interleukin-6 and C-reactive protein in healthy men. *Am J Cardiol* 2005; 95(10): 1258-60.
161. MacKenzie A, Wilson HL, Kiss-Toth E, et al. Rapid secretion of interleukin-1beta by microvesicle shedding. *Immunity* 2001; 15(5): 825-35.
162. Mezentsev A, Merks RM, O'Riordan E, et al. Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. *Am J Physiol Heart Circ Physiol* 2005; 289(3): H1106-14.
163. Ou ZJ, Chang FJ, Luo D, et al. Endothelium-derived microparticles inhibit angiogenesis in the heart and enhance the inhibitory effects of hypercholesterolemia on angiogenesis. *Am J Physiol Endocrinol Metab* 2011; 300(4): E661-8.
164. Tsimmerman G, Roguin A, Bachar A, et al. Involvement of microparticles in diabetic vascular complications. *Thromb Haemost* 2011; 106(2): 310-21.
165. Machlus KR, Italiano JE, Jr. The incredible journey: From megakaryocyte development to platelet formation. *J Cell Biol* 2013; 201(6): 785-96.
166. Kapur R, Zufferey A, Boilard E, et al. Nouvelle cuisine: platelets served with inflammation. *J Immunol* 2015; 194(12): 5579-87.
167. Morrell CN, Aggrey AA, Chapman LM, et al. Emerging roles for platelets as immune and inflammatory cells. *Blood* 2014; 123(18): 2759-67.
168. Varon D, Shai E. Platelets and their microparticles as key players in pathophysiological responses. *J Thromb Haemost* 2015; 13 Suppl 1: S40-6.
169. Badimon L, Suades R, Fuentes E, et al. Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis. *Front Pharmacol* 2016; 7: 293.
170. Landry P, Plante I, Ouellet DL, et al. Existence of a microRNA pathway in anucleate platelets. *Nat Struct Mol Biol* 2009; 16(9): 961-6.
171. Laffont B, Corduan A, Ple H, et al. Activated platelets can deliver mRNA regulatory Ago2*microRNA complexes to endothelial cells via microparticles. *Blood* 2013; 122(2): 253-61.
172. Pierce GF, Mustoe TA, Lingelbach J, et al. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. *J Cell Biol* 1989; 109(1): 429-40.
173. Ducheux AC, Boudreau LH, Naika GS, et al. Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA. *Proc Natl Acad Sci U S A* 2015; 112(27): E3564-73.
174. Brown GT, McIntyre TM. Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1beta-rich microparticles. *J Immunol* 2011; 186(9): 5489-96.
175. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. *Science* 2010; 327(5965): 580-3.
176. Boudreau LH, Ducheux AC, Cloutier N, et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. *Blood* 2014; 124(14): 2173-83.
177. Laffont B, Corduan A, Rousseau M, et al. Platelet microparticles reprogram macrophage gene expression and function. *Thromb Haemost* 2016; 115(2): 311-23.
178. Escolar G, Leistikow E, White JG. The fate of the open canalicular system in surface and suspension-activated platelets. *Blood* 1989; 74(6): 1983-8.

179. Tersteeg C, Heijnen HF, Eckly A, et al. FLOW-induced PROtrusions (FLIPRs): a platelet-derived platform for the retrieval of microparticles by monocytes and neutrophils. *Circ Res* 2014; 114(5): 780-91.
180. Yano Y, Kambayashi J, Shiba E, et al. The role of protein phosphorylation and cytoskeletal reorganization in microparticle formation from the platelet plasma membrane. *Biochem J* 1994; 299 (Pt 1): 303-8.
181. Gitz E, Pollitt AY, Gitz-Francois JJ, et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. *Blood* 2014; 124(14): 2262-70.
182. Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. *Nat Rev Rheumatol* 2012; 8(9): 534-42.
183. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. *Nat Rev Rheumatol* 2015; 11(12): 693-704.
184. Sims PJ, Wiedmer T. Repolarization of the membrane potential of blood platelets after complement damage: evidence for a Ca⁺⁺-dependent exocytotic elimination of C5b-9 pores. *Blood* 1986; 68(2): 556-61.
185. Hugel B, Socie G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. *Blood* 1999; 93(10): 3451-6.
186. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. *Blood* 2013; 121(25): 4985-96; quiz 5105.
187. Suades R, Padro T, Vilahur G, et al. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. *Thromb Haemost* 2012; 108(6): 1208-19.
188. Willerson JT, Golino P, Eidt J, et al. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. *Circulation* 1989; 80(1): 198-205.
189. Lee YJ, Jy W, Horstman LL, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. *Thromb Res* 1993; 72(4): 295-304.
190. Chiva-Blanch G, Suades R, Crespo J, et al. Microparticle Shedding from Neural Progenitor Cells and Vascular Compartment Cells Is Increased in Ischemic Stroke. *PLoS One* 2016; 11(1): e0148176.
191. Lopes-Virella MF, Virella G. Immune mechanisms of atherosclerosis in diabetes mellitus. *Diabetes* 1992; 41 Suppl 2: 86-91.
192. Mullier F, Minet V, Bailly N, et al. Platelet microparticle generation assay: a valuable test for immune heparin-induced thrombocytopenia diagnosis. *Thromb Res* 2014; 133(6): 1068-73.
193. Falanga A, Tartari CJ, Marchetti M. Microparticles in tumor progression. *Thromb Res* 2012; 129 Suppl 1: S132-6.
194. Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. *Curr Opin Hematol* 2013; 20(5): 472-7.
195. Pattanapanyasat K, Gonwong S, Chaichompoo P, et al. Activated platelet-derived microparticles in thalassaemia. *Br J Haematol* 2007; 136(3): 462-71.
196. Agouti I, Cointe S, Robert S, et al. Platelet and not erythrocyte microparticles are procoagulant in transfused thalassaemia major patients. *Br J Haematol* 2015; 171(4): 615-24.
197. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. *Blood* 2015; 126(5): 582-8.

198. Pap E. The role of microvesicles in malignancies. *Adv Exp Med Biol* 2011; 714: 183-99.
199. Reid VL, Webster NR. Role of microparticles in sepsis. *Br J Anaesth* 2012; 109(4): 503-13.
200. Panes O, Matus V, Saez CG, et al. Human platelets synthesize and express functional tissue factor. *Blood* 2007; 109(12): 5242-50.
201. Schwertz H, Tolley ND, Foulks JM, et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. *J Exp Med* 2006; 203(11): 2433-40.
202. Bouchard BA, Mann KG, Butenas S. No evidence for tissue factor on platelets. *Blood* 2010; 116(5): 854-5.
203. Osterud B. The role of platelets in decrypting monocyte tissue factor. *Semin Hematol* 2001; 38(4 Suppl 12): 2-5.
204. Hrachovinova I, Cambien B, Hafezi-Moghadam A, et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. *Nat Med* 2003; 9(8): 1020-5.
205. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. *J Exp Med* 2003; 197(11): 1585-98.
206. Gyorgy B, Szabo TG, Turiak L, et al. Improved flow cytometric assessment reveals distinct microvesicle (cell-derived microparticle) signatures in joint diseases. *PLoS One* 2012; 7(11): e49726.
207. Milasan A, Tessandier N, Tan S, et al. Extracellular vesicles are present in mouse lymph and their level differs in atherosclerosis. *J Extracell Vesicles* 2016; 5: 31427.
208. Cloutier N, Tan S, Boudreau LH, et al. The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. *EMBO Mol Med* 2013; 5(2): 235-49.
209. Dinkla S, van Cranenbroek B, van der Heijden WA, et al. Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin. *Blood* 2016; 127(16): 1976-86.
210. Wang T, Sun X, Zhao J, et al. Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood. *Ann Rheum Dis* 2015; 74(6): 1293-301.
211. Cloutier N, Pare A, Farndale RW, et al. Platelets can enhance vascular permeability. *Blood* 2012; 120(6): 1334-43.
212. Stormorken H, Holmsen H, Sund R, et al. Studies on the haemostatic defect in a complicated syndrome. An inverse Scott syndrome platelet membrane abnormality? *Thromb Haemost* 1995; 74(5): 1244-51.
213. Misceo D, Holmgren A, Louch WE, et al. A dominant STIM1 mutation causes Stormorken syndrome. *Hum Mutat* 2014; 35(5): 556-64.
214. Nesin V, Wiley G, Kousi M, et al. Activating mutations in STIM1 and ORAI1 cause overlapping syndromes of tubular myopathy and congenital miosis. *Proc Natl Acad Sci U S A* 2014; 111(11): 4197-202.
215. Freyssinet JM. Cellular microparticles: what are they bad or good for? *J Thromb Haemost* 2003; 1(7): 1655-62.
216. Kim HK, Song KS, Chung JH, et al. Platelet microparticles induce angiogenesis in vitro. *Br J Haematol* 2004; 124(3): 376-84.

217. Aatonen M, Gronholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. *Semin Thromb Hemost* 2012; 38(1): 102-13.
218. Pluskota E, Woody NM, Szpak D, et al. Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. *Blood* 2008; 112(6): 2327-35.
219. Wang JG, Williams JC, Davis BK, et al. Monocytic microparticles activate endothelial cells in an IL-1beta-dependent manner. *Blood* 2011; 118(8): 2366-74.
220. Liu ML, Reilly MP, Casasanto P, et al. Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles. *Arterioscler Thromb Vasc Biol* 2007; 27(2): 430-5.
221. Timar CI, Lorincz AM, Csepányi-Komi R, et al. Antibacterial effect of microvesicles released from human neutrophilic granulocytes. *Blood* 2013; 121(3): 510-8.
222. Sarkar A, Mitra S, Mehta S, et al. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. *PLoS One* 2009; 4(9): e7140.
223. Szczepanski MJ, Szajnik M, Welsh A, et al. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. *Haematologica* 2011; 96(9): 1302-9.
224. Benameur T, Chappard D, Fioleau E, et al. Plasma cells release membrane microparticles in a mouse model of multiple myeloma. *Micron* 2013; 54-55: 75-81.
225. Domnikova NP, Dolgikh TY, Sholenberg EV, et al. Blood microvesicles during chronic lymphoproliferative diseases. *Bull Exp Biol Med* 2013; 156(1): 94-7.
226. Fujimi S, Ogura H, Tanaka H, et al. Increased production of leukocyte microparticles with enhanced expression of adhesion molecules from activated polymorphonuclear leukocytes in severely injured patients. *J Trauma* 2003; 54(1): 114-9; discussion 9-20.
227. Nieuwland R, Berckmans RJ, McGregor S, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. *Blood* 2000; 95(3): 930-5.
228. Fujimi S, Ogura H, Tanaka H, et al. Activated polymorphonuclear leukocytes enhance production of leukocyte microparticles with increased adhesion molecules in patients with sepsis. *J Trauma* 2002; 52(3): 443-8.
229. Dalli J, Montero-Melendez T, Norling LV, et al. Heterogeneity in neutrophil microparticles reveals distinct proteome and functional properties. *Mol Cell Proteomics* 2013; 12(8): 2205-19.
230. Lorincz AM, Schutte M, Timar CI, et al. Functionally and morphologically distinct populations of extracellular vesicles produced by human neutrophilic granulocytes. *J Leukoc Biol* 2015; 98(4): 583-9.
231. Feske S. Calcium signalling in lymphocyte activation and disease. *Nat Rev Immunol* 2007; 7(9): 690-702.
232. Bartels K, Grenz A, Eltzschig HK. Hypoxia and inflammation are two sides of the same coin. *Proc Natl Acad Sci U S A* 2013; 110(46): 18351-2.
233. Bucki R, Bachelot-Loza C, Zachowski A, et al. Calcium induces phospholipid redistribution and microvesicle release in human erythrocyte membranes by independent pathways. *Biochemistry* 1998; 37(44): 15383-91.
234. Pasquet JM, Dachary-Prigent J, Nurden AT. Calcium influx is a determining factor of calpain activation and microparticle formation in platelets. *Eur J Biochem* 1996; 239(3): 647-54.

235. VanWijk MJ, Nieuwland R, Boer K, et al. Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction? *Am J Obstet Gynecol* 2002; 187(2): 450-6.
236. Szabo GT, Tarr B, Paloczi K, et al. Critical role of extracellular vesicles in modulating the cellular effects of cytokines. *Cell Mol Life Sci* 2014; 71(20): 4055-67.
237. Vince RV, Christmas B, Midgley AW, et al. Hypoxia mediated release of endothelial microparticles and increased association of S100A12 with circulating neutrophils. *Oxid Med Cell Longev* 2009; 2(1): 2-6.
238. Suades R, Padro T, Badimon L. The Role of Blood-Borne Microparticles in Inflammation and Hemostasis. *Semin Thromb Hemost* 2015; 41(6): 590-606.
239. Osteikoetxea X, Nemeth A, Sodar BW, et al. Extracellular vesicles in cardiovascular disease: are they Jedi or Sith? *J Physiol* 2016; 594(11): 2881-94.
240. Jungel A, Distler O, Schulze-Horsel U, et al. Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. *Arthritis Rheum* 2007; 56(11): 3564-74.
241. Buzas EI, Gyorgy B, Nagy G, et al. Emerging role of extracellular vesicles in inflammatory diseases. *Nat Rev Rheumatol* 2014; 10(6): 356-64.
242. Meziani F, Tesse A, David E, et al. Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. *Am J Pathol* 2006; 169(4): 1473-83.
243. Mortaza S, Martinez MC, Baron-Menguy C, et al. Detrimental hemodynamic and inflammatory effects of microparticles originating from septic rats. *Crit Care Med* 2009; 37(6): 2045-50.
244. Gasser O, Schifferli JA. Activated polymorphonuclear neutrophils disseminate anti-inflammatory microparticles by ectocytosis. *Blood* 2004; 104(8): 2543-8.
245. Eken C, Gasser O, Zenhausern G, et al. Polymorphonuclear neutrophil-derived ectosomes interfere with the maturation of monocyte-derived dendritic cells. *J Immunol* 2008; 180(2): 817-24.
246. Sadallah S, Eken C, Martin PJ, et al. Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. *J Immunol* 2011; 186(11): 6543-52.
247. Mostefai HA, Bourget JM, Meziani F, et al. Interleukin-10 controls the protective effects of circulating microparticles from patients with septic shock on tissue-engineered vascular media. *Clin Sci (Lond)* 2013; 125(2): 77-85.
248. Turbica I, Gallais Y, Gueguen C, et al. Ectosomes from neutrophil-like cells down-regulate nickel-induced dendritic cell maturation and promote Th2 polarization. *J Leukoc Biol* 2015; 97(4): 737-49.
249. Suades R, Padro T, Alonso R, et al. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients. *Thromb Haemost* 2014; 111(1): 111-21.
250. Sarlon-Bartoli G, Bennis Y, Lacroix R, et al. Plasmatic level of leukocyte-derived microparticles is associated with unstable plaque in asymptomatic patients with high-grade carotid stenosis. *J Am Coll Cardiol* 2013; 62(16): 1436-41.
251. Chiva-Blanch G, Bratseth V, Ritschel V, et al. Monocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients. *Int J Cardiol* 2017; 227: 876-81.

252. Chiva-Blanch G, Suades R, Crespo J, et al. CD3(+)/CD45(+) and SMA-alpha(+) circulating microparticles are increased in individuals at high cardiovascular risk who will develop a major cardiovascular event. *Int J Cardiol* 2016; 208: 147-9.
253. Chironi G, Simon A, Hugel B, et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. *Arterioscler Thromb Vasc Biol* 2006; 26(12): 2775-80.
254. Gyorgy B, Szabo TG, Pasztoi M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. *Cell Mol Life Sci* 2011; 68(16): 2667-88.
255. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. *Am J Pathol* 1996; 149(2): 367-80.
256. Mallat Z, Hugel B, Ohan J, et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. *Circulation* 1999; 99(3): 348-53.
257. Martin S, Tesse A, Hugel B, et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. *Circulation* 2004; 109(13): 1653-9.
258. Yang C, Mwaikambo BR, Zhu T, et al. Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways. *Am J Physiol Regul Integr Comp Physiol* 2008; 294(2): R467-76.
259. Yang C, Gagnon C, Hou X, et al. Low density lipoprotein receptor mediates anti-VEGF effect of lymphocyte T-derived microparticles in Lewis lung carcinoma cells. *Cancer Biol Ther* 2010; 10(5): 448-56.
260. Miguet L, Bechade G, Fornecker L, et al. Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis. *J Proteome Res* 2009; 8(7): 3346-54.
261. Di Noto G, Paolini L, Zendrini A, et al. C-src enriched serum microvesicles are generated in malignant plasma cell dyscrasia. *PLoS One* 2013; 8(8): e70811.
262. Zinger A, Latham SL, Combes V, et al. Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients. *Mult Scler* 2016; 22(14): 1883-7.
263. Allan D, Limbrick AR, Thomas P, et al. Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. *Nature* 1982; 295(5850): 612-3.
264. Allan D, Thomas P, Limbrick AR. Microvesiculation and sphingomyelinase activation in chicken erythrocytes treated with ionophore A23187 and Ca²⁺. *Biochim Biophys Acta* 1982; 693(1): 53-67.
265. Wagner GM, Chiu DT, Yee MC, et al. Red cell vesiculation--a common membrane physiologic event. *J Lab Clin Med* 1986; 108(4): 315-24.
266. Whitlow M, Iida K, Marshall P, et al. Cells lacking glycan phosphatidylinositol-linked proteins have impaired ability to vesiculate. *Blood* 1993; 81(2): 510-6.
267. Hagerstrand H, Bobrowska-Hagerstrand M, Lillsunde I, et al. Vesiculation induced by amphiphiles and ionophore A23187 in porcine platelets: a transmission electron microscopic study. *Chem Biol Interact* 1996; 101(2): 115-26.
268. Hagerstrand H, Kralj-Iglic V, Bobrowska-Hagerstrand M, et al. Membrane skeleton detachment in spherical and cylindrical microexovesicles. *Bull Math Biol* 1999; 61(6): 1019-30.
269. Bratosin D, Estaquier J, Petit F, et al. Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria. *Cell Death Differ* 2001; 8(12): 1143-56.

270. Igljic A, Veranic P, Jezernik K, et al. Spherocyte shape transformation and release of tubular nanovesicles in human erythrocytes. *Bioelectrochemistry* 2004; 62(2): 159-61.
271. Greenwalt TJ. The how and why of exocytic vesicles. *Transfusion* 2006; 46(1): 143-52.
272. Giannopoulos G, Oudatzis G, Paterakis G, et al. Red blood cell and platelet microparticles in myocardial infarction patients treated with primary angioplasty. *Int J Cardiol* 2014; 176(1): 145-50.
273. Suades R, Padro T, Vilahur G, et al. Growing thrombi release increased levels of CD235a(+) microparticles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients. *J Thromb Haemost* 2015; 13(10): 1776-86.
274. Setty BN, Kulkarni S, Rao AK, et al. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. *Blood* 2000; 96(3): 1119-24.
275. van Tits LJ, van Heerde WL, Landburg PP, et al. Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. *Biochem Biophys Res Commun* 2009; 390(1): 161-4.
276. Mahfoudhi E, Lecluse Y, Driss F, et al. Red cells exchanges in sickle cells disease lead to a selective reduction of erythrocytes-derived blood microparticles. *Br J Haematol* 2012; 156(4): 545-7.
277. Tantawy AA, Adly AA, Ismail EA, et al. Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications. *Platelets* 2013; 24(8): 605-14.
278. Pattanapanyasat K, Noulisri E, Fucharoen S, et al. Flow cytometric quantitation of red blood cell vesicles in thalassemia. *Cytometry B Clin Cytom* 2004; 57(1): 23-31.
279. Westerman M, Pizzey A, Hirschman J, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. *Br J Haematol* 2008; 142(1): 126-35.
280. Oswald E, Streif W, Hermann M, et al. Intraoperatively salvaged red blood cells contain nearly no functionally active platelets, but exhibit formation of microparticles: results of a pilot study in orthopedic patients. *Transfusion* 2010; 50(2): 400-6.
281. Donadee C, Raat NJ, Kaniyas T, et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. *Circulation* 2011; 124(4): 465-76.
282. Hendrickson JE, Hod EA, Hudson KE, et al. Transfusion of fresh murine red blood cells reverses adverse effects of older stored red blood cells. *Transfusion* 2011; 51(12): 2695-702.
283. Liu C, Zhao W, Christ GJ, et al. Nitric oxide scavenging by red cell microparticles. *Free Radic Biol Med* 2013; 65: 1164-73.
284. Griffiths RE, Kupzig S, Cogan N, et al. Maturing reticulocytes internalize plasma membrane in glycophorin A-containing vesicles that fuse with autophagosomes before exocytosis. *Blood* 2012; 119(26): 6296-306.
285. Taraschi TF, Trelka D, Martinez S, et al. Vesicle-mediated trafficking of parasite proteins to the host cell cytosol and erythrocyte surface membrane in *Plasmodium falciparum* infected erythrocytes. *Int J Parasitol* 2001; 31(12): 1381-91.
286. van Beers EJ, Schaap MC, Berckmans RJ, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. *Haematologica* 2009; 94(11): 1513-9.

287. Gerotziapas GT, Van Dreden P, Chaari M, et al. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. *Thromb Haemost* 2012; 107(6): 1044-52.
288. Koshiar RL, Somajo S, Norstrom E, et al. Erythrocyte-derived microparticles supporting activated protein C-mediated regulation of blood coagulation. *PLoS One* 2014; 9(8): e104200.
289. Zecher D, Cumpelik A, Schifferli JA. Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement. *Arterioscler Thromb Vasc Biol* 2014; 34(2): 313-20.
290. Blum A. The possible role of red blood cell microvesicles in atherosclerosis. *Eur J Intern Med* 2009; 20(2): 101-5.
291. Camus SM, De Moraes JA, Bonnin P, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. *Blood* 2015; 125(24): 3805-14.
292. Camus SM, Gausseres B, Bonnin P, et al. Erythrocyte microparticles can induce kidney vaso-occlusions in a murine model of sickle cell disease. *Blood* 2012; 120(25): 5050-8.
293. Nourai M, Lee JS, Zhang Y, et al. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. *Haematologica* 2013; 98(3): 464-72.
294. Forest A, Pautas E, Ray P, et al. Circulating microparticles and procoagulant activity in elderly patients. *J Gerontol A Biol Sci Med Sci* 2010; 65(4): 414-20.
295. Owen BA, Xue A, Heit JA, et al. Procoagulant activity, but not number, of microparticles increases with age and in individuals after a single venous thromboembolism. *Thromb Res* 2011; 127(1): 39-46.
296. Toth B, Nikolajek K, Rank A, et al. Gender-specific and menstrual cycle dependent differences in circulating microparticles. *Platelets* 2007; 18(7): 515-21.
297. Preston RA, Jy W, Jimenez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. *Hypertension* 2003; 41(2): 211-7.
298. Amabile N, Cheng S, Renard JM, et al. Association of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study. *Eur Heart J* 2014; 35(42): 2972-9.
299. Suades R, Padro T, Alonso R, et al. High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis. *Thromb Haemost* 2015; 114(6): 1310-21.
300. Ferreira AC, Peter AA, Mendez AJ, et al. Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. *Circulation* 2004; 110(23): 3599-603.
301. Gordon C, Gudi K, Krause A, et al. Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. *Am J Respir Crit Care Med* 2011; 184(2): 224-32.
302. Mobarrez F, Antoniewicz L, Bosson JA, et al. The effects of smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy volunteers. *PLoS One* 2014; 9(2): e90314.
303. Pope CA, 3rd, Bhatnagar A, McCracken JP, et al. Exposure to Fine Particulate Air Pollution Is Associated With Endothelial Injury and Systemic Inflammation. *Circ Res* 2016; 119(11): 1204-14.

304. Esposito K, Ciotola M, Schisano B, et al. Endothelial microparticles correlate with endothelial dysfunction in obese women. *J Clin Endocrinol Metab* 2006; 91(9): 3676-9.
305. Stepanian A, Bourguignat L, Hennou S, et al. Microparticle increase in severe obesity: not related to metabolic syndrome and unchanged after massive weight loss. *Obesity (Silver Spring)* 2013; 21(11): 2236-43.
306. Gunduz Z, Dursun I, Tulpar S, et al. Increased endothelial microparticles in obese and overweight children. *J Pediatr Endocrinol Metab* 2012; 25(11-12): 1111-7.
307. Csongradi E, Nagy B, Jr., Fulop T, et al. Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients. *Thromb Haemost* 2011; 106(4): 683-92.
308. Diamant M, Nieuwland R, Pablo RF, et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. *Circulation* 2002; 106(19): 2442-7.
309. Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. *Diabetes* 2002; 51(9): 2840-5.
310. Koga H, Sugiyama S, Kugiyama K, et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. *J Am Coll Cardiol* 2005; 45(10): 1622-30.
311. Arteaga RB, Chirinos JA, Soriano AO, et al. Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. *Am J Cardiol* 2006; 98(1): 70-4.
312. Navasolava NM, Dignat-George F, Sabatier F, et al. Enforced physical inactivity increases endothelial microparticle levels in healthy volunteers. *Am J Physiol Heart Circ Physiol* 2010; 299(2): H248-56.
313. Miller VM, Lahr BD, Bailey KR, et al. Specific cell-derived microvesicles: Linking endothelial function to carotid artery intima-media thickness in low cardiovascular risk menopausal women. *Atherosclerosis* 2016; 246: 21-8.
314. Jayachandran M, Litwiller RD, Owen WG, et al. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. *Am J Physiol Heart Circ Physiol* 2008; 295(3): H931-H8.
315. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. *Circulation* 2000; 101(8): 841-3.
316. Bernal-Mizrachi L, Jy W, Jimenez JJ, et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. *Am Heart J* 2003; 145(6): 962-70.
317. Morel O, Hugel B, Jesel L, et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. *J Thromb Haemost* 2004; 2(7): 1118-26.
318. Matsumoto N, Nomura S, Kamihata H, et al. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. *Thromb Haemost* 2004; 91(1): 146-54.
319. Katopodis JN, Kolodny L, Jy W, et al. Platelet microparticles and calcium homeostasis in acute coronary ischemias. *Am J Hematol* 1997; 54(2): 95-101.
320. Tan KT, Tayebjee MH, Macfadyen RJ, et al. Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. *Platelets* 2005; 16(6): 368-71.

321. Empana JP, Boulanger CM, Tafflet M, et al. Microparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and Inflammation in sudden DEath) study. *Eur Heart J Acute Cardiovasc Care* 2015; 4(1): 28-36.
322. Simak J, Gelderman MP, Yu H, et al. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. *J Thromb Haemost* 2006; 4(6): 1296-302.
323. Kuriyama N, Nagakane Y, Hosomi A, et al. Evaluation of factors associated with elevated levels of platelet-derived microparticles in the acute phase of cerebral infarction. *Clin Appl Thromb Hemost* 2010; 16(1): 26-32.
324. Williams JB, Jauch EC, Lindsell CJ, et al. Endothelial microparticle levels are similar in acute ischemic stroke and stroke mimics due to activation and not apoptosis/necrosis. *Acad Emerg Med* 2007; 14(8): 685-90.
325. Jung KH, Chu K, Lee ST, et al. Circulating endothelial microparticles as a marker of cerebrovascular disease. *Ann Neurol* 2009; 66(2): 191-9.
326. Tan KT, Tayebjee MH, Lynd C, et al. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. *Ann Med* 2005; 37(1): 61-6.
327. Nomura S, Imamura A, Okuno M, et al. Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shear-induced microparticle generation by cytokines. *Thromb Res* 2000; 98(4): 257-68.
328. van der Zee PM, Biro E, Ko Y, et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. *Clin Chem* 2006; 52(4): 657-64.
329. Dursun I, Poyrazoglu HM, Gunduz Z, et al. The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease. *Nephrol Dial Transplant* 2009; 24(8): 2511-8.
330. Amabile N, Guerin AP, Leroyer A, et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. *J Am Soc Nephrol* 2005; 16(11): 3381-8.